



2026 ASCP
ANNUAL MEETING

PROGRAM BOOK

PSYCHIATRY AND AI: PROMISES, PERILS, AND PATHWAYS FORWARD

LOEWS MIAMI BEACH HOTEL | MIAMI, FLORIDA

MAY 26-29, 2026



ASCP

American Society of
Clinical Psychopharmacology



Dear Friends and Colleagues,

It is my great honor to welcome you to the 2026 ASCP Annual Meeting in Miami, FL, themed “Psychiatry and AI: Promises, Perils, and Pathways Forward.” This meeting is more than just a series of sessions—it is a space for collaboration, innovation, and inspiration. Over the course of our time together, we will exchange ideas, challenge perspectives, and explore new opportunities to better serve our communities and elevate our profession.

I want to thank our outstanding Program Committee for the Annual Meeting, led by Drs. Tiffany Farchione, Carlos Blanco, Manish Jha and Dan Iosifescu, as well as the Review Subcommittee, for their tireless work in vetting an extraordinary number of submitted panels, workshops and related programs. Their coordinating efforts are especially appreciated at a time of unprecedented challenges facing our scientific community and uncertainties about the future and scope of federally supported clinical research and infrastructure.

Highlights of our meeting include:

- The Keynote Plenary session by Dr. Roy Perlis discussing AI Beyond Evil Robots: Ensuring Transformative Means Better.



- Attendees are invited to attend the luncheon on Tuesday hosted by the Inclusivity Committee.
- Drs. Matthew Macaluso and Richard Shelton Tuesday workshop showcasing the following presentation: Towards an International, Standardized Model Psychopharmacology Curriculum for Psychiatry Residency Training: A Competency-Based Framework for Implementation.
- A lecture on Wednesday morning presented by Dr. Michael Thase, the winner of this year's Donald Klein Lifetime Achievement Award, and Dr. Leslie Citrome, the winner of this year's Henry Nasrallah Award for Excellence in Psychopharmacology Education.
- ASCP will be hosting two satellite CME symposiums: Wednesday evening and Thursday morning.
- Early- and mid-career attendees are invited to attend an interactive workshop hosted by the Early Career Committee on Thursday afternoon, titled Building Collaborative Capacity in Early Career Psychopharmacology: Strategies for Effective Partnerships Across Academia, Industry, and Clinical Practice.
- And finally, we once again have an outstanding group of New Investigator Awardees who will showcase their research efforts throughout the meeting.

A special thanks to our sponsors, who have generously supported our meeting, as well as to our friends at Parthenon Management Group, who have worked so diligently to help plan this meeting and assure its success.

Thank you for being here and for your continued dedication to excellence. We look forward to a productive and inspiring event. Enjoy the meeting!

Anita H. Clayton, M.D.

President

American Society of Clinical Psychopharmacology (ASCP)



Welcome to the ASCP Annual Meeting

On behalf of the ASCP Program Committee for the Annual Meeting and Review Sub-Committee, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2026 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

2026 Program Highlights

- **Tuesday, May 26th:**
 - Meeting Opening
 - Inclusivity Luncheon (RSVP Only)
 - Pharmaceutical Pipeline
- **Wednesday, May 27th:**
 - 27th Annual Fun Run/Walk
 - Regulatory Plenary: *AI-Based Tools in CNS Drug Development: A Regulatory Framework for Clinical Trial Applications*
 - Henry Nasrallah Awardee: Leslie Citrome, M.D., M.P.H.: *The Tyranny of the P-value: Effect Size Matters*
 - ASCP Lifetime Awardee Talk by Michael E. Thase, M.D.: *A Short Journey through a 50 Years of Progress in the Treatment of Depression*
 - Poster Session I
 - Clinical Updates in Neurotherapeutics
 - Individual Research Reports
 - ASCP Reception
 - Satellite Symposium: *Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders*
- **Thursday, May 28th:**
 - Satellite Symposium: *Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia*



- Keynote Plenary: *AI Beyond Evil Robots: Ensuring Transformative Means Better*
- Poster Session II
- Plenary Panel: *Artificial Intelligence: Understanding the Present and Anticipating the Future*
- **The New Investigator Program**
 - A closed workshop for 20 New Investigators and informal breakfast sessions
- **Workshops:** 2-hour intensive interactive sessions focused on problems and solutions on Tuesday afternoon
- * **Clinical Track** – Sessions focused on topics of immediate clinical relevance
- ~ **Not Accredited** – Per the new ACCME guidelines, these sessions cannot be accredited
- # **Child/Adolescent Track** – Sessions focused on topics of child and adolescent relevance
- ^ **Academic Track** – Sessions focused on topics of academic relevance
- + **DEI Track** – Sessions focused on topics of DEI relevance

Organization

- The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
 - The Program Committee for the Annual Meeting (PCAN) organizes the meeting.
 - The Review Sub-Committee evaluates submitted proposals and develops program innovations.
- Federal Agency & Other Funding Agency collaborations:
 - NIAAA – National Institute on Alcohol Abuse and Alcoholism
 - NIDA – National Institute of Drug Abuse
 - PCORI – Patient-Centered Outcomes Research Institute
 - VA – Veterans Administration
 - DHA – Defense Health Agency
- Society collaboration:
 - American Brain Coalition (ABC)
- Parthenon Management Group organizes the ASCP Annual Meeting.



And Remember

- The Fun Run/Walk is Wednesday, May 27th at 6:30 a.m. All are welcome to join!
- The ASCP Reception is Wednesday, May 27th from 6:00 p.m. – 7:00 p.m. All are welcome to join!

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

Tiffany Farchione, M.D.
PCAN Co-Chair

Carlos Blanco, M.D.
PCAN Co-Chair


Manish Jha, M.D.
Review Sub-Committee Co-Chair

Dan Iosifescu, M.D., M.Sc.
Review Sub-Committee Co-Chair




Loews Miami Beach Hotel Meeting Space Map

Second Level



Third Level





Award Winners

Recipient of the Donald Klein Lifetime Achievement Award



Michael E. Thase, M.D.

Perelman School of Medicine of the University of Pennsylvania

Dr. Michael E. Thase is Professor of Psychiatry, Perelman School of Medicine (University of Pennsylvania) and Philadelphia VAMC. A graduate of The Ohio State University College of Medicine, Professor Thase completed residency and fellowship at the University of Pittsburgh Medical Center, where he rose to the rank of Professor and Chief, Division of Academic Adult Psychiatry before his 2007 move to Philadelphia. Professor Thase is renowned as a teacher, mentor, administrator, researcher and clinician. He is a Distinguished Life Fellow of the APA and a Founding Fellow of the Academy of Cognitive Therapy. A past president of the American Society of Clinical Psychopharmacology, he recently was selected to receive the Society's Donald F Klein award for Lifetime Achievement. Professor Thase is a member of advisory boards for the Anxiety and Depressive Disorders Association, the National Network of Depression Centers, the Depression and Bipolar Support



Alliance and the American Foundation for Suicide Prevention. In 2018 he was elected to the membership of Penn Medicine's Academy of Master Clinicians, an honor bestowed to less than 2% of the medical school's faculty. One of the world's most highly cited psychiatrists, Professor Thase's 1300+ publications include 16 citation classics. Among the 18 books that Professor Thase as authored, co-authored or edited, is the award-winning Learning Cognitive Therapy, now in its second edition. Professor Thase's research has been continuously funded by various federal agencies for the past 38 years and currently focuses on novel therapies for difficult to treat depressive disorders, comparative treatment effectiveness of therapies for Post-Traumatic Stress Disorder and dissemination and implementation of cost-effective forms of cognitive behavior therapy.

Recipient of the Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award



Mary Hobart, Ph.D.

Otsuka Pharmaceutical Development and Commercialization, Inc.

Brexipiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Randomized Clinical Trial

Dr. Hobart is currently the Senior Vice President of Global R&D Evidence at Otsuka Pharmaceutical Development & Commercialization, Inc.



(OPDC). She has worked at the University of Maryland School of Medicine within the Psychiatry department. She also holds an undergraduate degree in pre-medicine and psychology and a graduate degree in clinical neuropsychology.

Recipient of the Henry Nasrallah Award for Excellence in Clinical Psychopharmacology Education



Leslie Citrome, M.D., M.P.H.

New York Medical College

Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, and Adjunct Professor at the Northwestern Feinberg School of Medicine in Chicago, Illinois. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York and Professor of Psychiatry at the New York University School of Medicine. In 2010, after leaving State service, Dr. Citrome became engaged as a consultant in clinical trial design and interpretation. He remained clinically active providing assistance to patients and their families through the Assertive Community Treatment program operated by the Mental Health Association of



Rockland County through 2025. Dr. Citrome is a former President of the American Society of Clinical Psychopharmacology 2021-2023, as well as Board Member 2012-2025. Dr. Citrome is the author or co-author of over 600 original research reports, reviews, and book chapters in the scientific literature, is Editor-in-Chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis, and Editor of the "ASCP Corner" in the Journal of Clinical Psychiatry. He served as the senior author of the 2022 Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research, on behalf of the International Society for Medical Publication Professionals, and has served as a Board Member of the World Association of Medical Editors. Dr. Citrome has lectured extensively about the importance of quantifying clinical relevance of research findings using Number Needed to Treat throughout the Americas, Europe, Asia, Australasia, and the Middle East. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow (Emeritus) of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).



2025-2026 ASCP Nina Schooler Early Career Research Award



Adam Fijtman, M.D., Ph.D.

National Institute of Mental Health

Research Title: *Ketamine's Impact on Cognition in Individuals with Bipolar Depression and Previous Psychotic Symptoms*

Dr. Adam Fijtman received his medical degree and Ph.D. in Psychiatry and Behavioral Sciences from the Federal University of Rio Grande do Sul in Brazil. He completed his residency in Psychiatry at Duke University School of Medicine and a Clinical Research Fellowship in the Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health. Dr. Fijtman studies cognitive deficits in bipolar disorder, with a focus on biomarkers and novel therapeutic approaches.



New Investigator Awardees

 **Sara Di Luch, B.Sc.**

University of Toronto

 **Naomi Gaggi, Ph.D.**

New York University Grossman
School of Medicine

 **Clotilde Guidetti, M.D.**

Department of Psychiatry,
Massachusetts General Hospital,
and Harvard Medical School

 **Morgan Hardy, M.D.,
M.P.H.**

Department of Psychiatry, Yale
University School of Medicine

 **Shabnam Hossein, Ph.D.**

University of Pittsburgh

 **Hiroe Hu, D.O.**

National Institute of Mental
Health

 **Yuefeng Huang, Ph.D.**

Icahn School of Medicine At
Mount Sinai

 **Deepak Kaji, M.D., Ph.D.,
B.A.**

Icahn School of Medicine At
Mount Sinai

 **Sarah King, Ph.D.**

Icahn School of Medicine at
Mount Sinai

 **Gia Han Le, B.Sc., Ph.D.**

Institute of Medical Science,
University of Toronto

 **Songjun Li, M.D., Ph.D.**

Yale

 **Orly Lipsitz, M.A.**

University of Toronto

 **Cristian-Daniel Llach
Lopez, M.D.**

University of Toronto

 **Grace Marley, Pharm.D.**

University of North Carolina
Eshelman School of Pharmacy

 **Natalie McClain, B.A.**

Icahn School of Medicine At
Mount Sinai

 **Henrique Oliva, B.Sc.,
M.Sc., M.D., Ph.D.**

Yale University School of
Medicine



 **Sean O’Sullivan, M.D.,
Ph.D.**

The University of Texas At
Austin

 **Diana Orsini, M.Sc.,
M.P.H., B.S.**

University of Toronto

 **Niki Sabetfakhri, M.S.**

University of Illinois At Chicago
College of Medicine

 **John Williams, M.S., Ph.D.**

Stony Brook University School
of Medicine



Featured Speakers

Regulatory Plenary: AI-Based Tools in CNS Drug Development: A Regulatory Framework for Clinical Trial Applications

Wednesday, May 27th: 8:30 a.m. – 10:00 a.m.



Tiffany Farchione, M.D.

US Food and Drug Administration

Dr. Tiffany Farchione, M.D. received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr.

Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, Dr. Farchione was affiliated with the University of Pittsburgh Medical Center and was on the faculty of the University of Pittsburgh. As the Director of the Division of Psychiatry at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under investigational new drug applications, and the review of all new drug applications and supplements for new psychiatric drug claims.



Valentina Mantua, M.D., Ph.D.

Center for Drug Evaluation and Research,
Food and Drug

Dr. Valentina Mantua, M.D., Ph.D., is Associate Director for Regulatory Science in the Office of Neuroscience at FDA's Center for Drug Evaluation and Research (CDER). She leads initiatives to advance innovative methods and tools in clinical trials and represents the Agency in pre-competitive collaborations with partners including NIH and

FNIH. Before joining FDA in 2019, Dr. Mantua served as a delegate of the Italian Medicines Agency (AIFA) to several committees and working parties of the European Medicines Agency (EMA) and practiced as a board-certified psychiatrist in the UK at South London and Maudsley NHS Foundation Trust. She is an active committee member of the American Society of Clinical Psychopharmacology (ASCP). Dr. Mantua received her M.D. and psychiatry residency training from Sapienza University of Rome and a Ph.D. in Neurobiology of Affective Disorders from the University of Pisa.



Qi Liu, Ph.D., M.Stat., FCP

Center for Drug Evaluation and Research, Food
and Drug Administration

Dr. Qi Liu, Ph.D., M.Stat., FCP is the Associate Director for Innovation & Partnership in the Office of Clinical Pharmacology (OCP)/ Office of Translational Sciences, CDER, FDA. She is a co-chair of CDER's AI Council and the lead of CDER AI Review Rapid Response Team. She is a member of the FDA-Wide AI Policy Coordination and Planning Council. She is also

on the executive board of CDER's Quantitative Medicine Center of Excellence. She helped establishing and has been directing the OCP



Innovative Data Analytics Program (focusing on AI, Real-world data and digital health) and AI review team. She had the experience leading Physiological Based Pharmacokinetic Modeling and Simulation Oversight Board and co-leading Biologics Oversight Board. During her career at the FDA, she also contributed to over 200 NDA/sNDA/BLA/sBLA reviews, and numerous IND reviews. She was on many working groups developing FDA guidance documents and Manual of Policies & Procedures.



Bernard Fischer, M.D.

U.S. Food and Drug Administration

Dr. Bernard Fischer, M.D. is a psychiatrist and the acting Deputy Director of the Office of Neuroscience in the Office of New Drugs at the U.S. Food and Drug Administration (FDA). He provides regulatory oversight of development and marketing approval of drugs for psychiatric and neurologic disorders, addiction, anesthesia, and pain under investigational new drug applications (INDs) and new drug applications (NDAs). Prior to the FDA, he spent more than 10 years in academic medicine at the Maryland Psychiatric Research Center (MPRC) and the Department of Veterans Affairs. Dr. Fischer earned his medical degree from the Medical College of Virginia. He completed a 5-year research/clinical residency in psychiatry at the University of Maryland/Sheppard Pratt followed by a post-doctoral fellowship in mental illness research at the MPRC. He holds a master's degree in biomedical ethics and has been board certified in both psychiatry and addiction medicine. He has authored or co-authored more than 50 scientific publications.



Roberta Rasetti, M.D., Ph.D.
FDA/CDER/DP

Dr. Roberta Rasetti, M.D., Ph.D. joined the FDA in late 2020 as a physician in the Division of Psychiatry. She received her MD and PhD from the University of Turin, Italy, and completed an adult residency at the University of Pennsylvania, Department of Psychiatry. Prior to joining the FDA in 2020, Dr. Rasetti was

affiliated with the Georgetown University School of Medicine and was on the faculty of Georgetown University and a Clinical Fellow at the National Institute of Mental Health, where she focused on schizophrenia research. As a medical reviewer in the Division of Psychiatry at the FDA, Dr. Rasetti is involved in the review of new drug applications and supplements for new psychiatric drugs.

ASCP Lifetime Awardee Talk and Nasrallah Award Winner
Wednesday, May 27th: 10:15 a.m. – 11:45 a.m.



Leslie Citrome, M.D., M.P.H.
New York Medical College

Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, and Adjunct Professor at the Northwestern Feinberg School of Medicine in Chicago, Illinois. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S.

Kline Institute for Psychiatric Research in Orangeburg, New York and Professor of Psychiatry at the New York University School of Medicine. In 2010, after leaving State service, Dr. Citrome became engaged as a



consultant in clinical trial design and interpretation. He remained clinically active providing assistance to patients and their families through the Assertive Community Treatment program operated by the Mental Health Association of Rockland County through 2025. Dr. Citrome is a former President of the American Society of Clinical Psychopharmacology 2021-2023, as well as Board Member 2012-2025. Dr. Citrome is the author or co-author of over 600 original research reports, reviews, and book chapters in the scientific literature, is Editor-in-Chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis, and Editor of the "ASCP Corner" in the Journal of Clinical Psychiatry. He served as the senior author of the 2022 Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research, on behalf of the International Society for Medical Publication Professionals, and has served as a Board Member of the World Association of Medical Editors. Dr. Citrome has lectured extensively about the importance of quantifying clinical relevance of research findings using Number Needed to Treat throughout the Americas, Europe, Asia, Australasia, and the Middle East. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow (Emeritus) of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).



Michael E. Thase, M.D.

Perelman School of Medicine (University of Pennsylvania) and Philadelphia VAMC.

Dr. Michael E. Thase is Professor of Psychiatry, Perelman School of Medicine (University of Pennsylvania) and Philadelphia VAMC. A graduate The Ohio State University College Medicine, Professor Thase completed residency and fellowship at the University of Pittsburgh Medical Center, where he rose to

the rank of Professor and Chief, Division of Academic Adult Psychiatry before his 2007 move to Philadelphia. Professor Thase is renowned as a teacher, mentor, administrator, researcher and clinician. He is a



Distinguished Life Fellow of the APA and a Founding Fellow of the Academy of Cognitive Therapy. A past president of the American Society of Clinical Psychopharmacology, he recently was selected to receive the Society's Donald F Klein award for Lifetime Achievement. Professor Thase is a member of advisory boards for the Anxiety and Depressive Disorders Association, the National Network of Depression Centers, the Depression and Bipolar Support Alliance and the American Foundation for Suicide Prevention. In 2018 he was elected to the membership of Penn Medicine's Academy of Master Clinicians, an honor bestowed to less than 2% of the medical school's faculty. One of the world's most highly cited psychiatrists, Professor Thase's 1300+ publications include 16 citation classics. Among the 18 books that Professor Thase has authored, co-authored or edited, is the award-winning Learning Cognitive Therapy, now in its second edition. Professor Thase's research has been continuously funded by various federal agencies for the past 38 years and currently focuses on novel therapies for difficult to treat depressive disorders, comparative treatment effectiveness of therapies for Post-Traumatic Stress Disorder and dissemination and implementation of cost-effective forms of cognitive behavior therapy.

Clinical Updates in Neurotherapeutics

Wednesday, May 27th: 1:30 p.m. – 3:00 p.m.



Joseph Goldberg, M.D.

Icahn School of Medicine at Mount Sinai

Dr. Joseph Goldberg is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City, and is the immediate-past president of ASCP. He is also deputy editor-in-chief of the Journal of Clinical Psychiatry. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, medical school at Northwestern University, and completed his psychiatry



residency and fellowship at the Payne Whitney Clinical of New York Hospital where he founded the bipolar disorders research clinic before moving to the Icahn School of Medicine at Mount Sinai. Dr. Goldberg has published over 250 peer reviewed publications and five books on topics related to clinical psychopharmacology in mood and psychotic disorders and is an active clinical investigator and educator in the treatment and outcome of major psychiatric disorders.



Andrew A. Nierenberg, M.D.
Massachusetts General Hospital

Dr. Andrew A. Nierenberg, M.D. is the Director of the Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, holds the Thomas P. Hackett, MD Endowed Chair at MGH, and is a Professor of Psychiatry at Harvard Medical School. In addition to directing the Dauten

Center, Dr. Nierenberg serves as the co-director of the MGH Center for Clinical Research Education. Dr. Nierenberg focuses on clinical trials for bipolar disorder and depression, with over 625 published papers and a Google Scholar h-index of over 130. He has been listed among The Best Doctors or Top Doctors in America for the treatment of mood and anxiety disorders yearly since 1994. He has been honored with the International Society for Bipolar Disorders Mogens Schou Award for Research, the Brain and Behavior Research Foundation's Colvin Prize, and the NAMI Scientific Research Award. Dr. Nierenberg is currently the PI of the Sequential Multiple Assignment of Treatment study for bipolar depression (SMART-BD) (that compares treatments for bipolar depression) funded by the Patient Centered Outcomes Research Institute (PCORI). He also leads the Bipolar Action Network, a Learning Health Network comprising multiple healthcare systems, which breaks down the barriers between clinical, research, and quality improvement activities to achieve better outcomes. Dr. Nierenberg has an active clinical practice, supervises and



teaches residents, serves on multiple nonprofit advocacy boards, is a member of multiple journal editorial boards, and is the editor-in-chief of *Psychiatric Annals*.



John M. Kane, M.D.

The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Dr. John M. Kane, MD served as chair of psychiatry for 34 years at the Zucker Hillside Hospital and is currently the Co-Director of the Institute of Behavioral Research at the Feinstein Institutes for Medical Research. He also served as the inaugural chair of Psychiatry at the Donald and Barbara Zucker

School of Medicine at Hofstra/Northwell for 12 years. He is the recipient of many awards, including the Lieber Prize, the APA's Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists, and the ASCP's Donald Klein Lifetime Achievement Award. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society. Dr. Kane has been the principal investigator on 24 U.S. National Institutes of Health grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 950 peer-reviewed papers and serves on the editorial boards of numerous journals.

**Lori Davis, M.D.**

Veterans Affairs Medical Center

Dr. Lori Davis, MD is Senior Research Psychiatrist at the Birmingham VA Health Care System and Adjunct Professor of Psychiatry in the Department of Psychiatry, University of Alabama Heersink School of Medicine, in Birmingham, AL. She received her undergraduate degree from Duke University and her medical degree from the University of North Carolina at Chapel Hill. She completed a psychiatry residency at the

University of Alabama at Birmingham. Dr. Davis has been designing and conducting clinical trials in mental health disorders for over 30 years under continuous peer-reviewed funding, resulting in over 130 publications. Her research aims to better understand the effects of pharmacotherapy, psychotherapy, vocational rehabilitation, mindfulness meditation, and other novel treatments for posttraumatic stress disorder (PTSD), depression, and substance use disorders.

**Keynote Plenary:****Thursday, May 28th: 8:15 a.m. - 9:15 a.m.**

Roy Perlis, M.D., MSc
Massachusetts General Hospital

Dr. Roy Perlis, MD MSc is Editor in Chief of JAMA+ AI, responsible for AI content across the JAMA Network, and Director of the Center for Quantitative Health at Massachusetts General Hospital. He serves as Vice Chair for Research and Ronald I. Dozoretz, MD Endowed Chair in the Department of Psychiatry at Massachusetts General

Brigham, and Professor of Psychiatry at Harvard Medical School. Dr. Perlis has authored more than 400 articles reporting original research in peer-reviewed journals ranging from Nature Genetics and Nature Neuroscience to JAMA and the New England Journal of Medicine, focused on development of novel treatments and biomarkers for brain diseases. Dr. Perlis was awarded the Depression and Bipolar Support Alliance's Gerald L. Klerman Young Investigator Award in 2010, and the DBSA's Senior Investigator Award in 2025; he is proud to serve as a scientific advisor to the DBSA. In his spare time, he enjoys tinkering with pinball machines and trying to grow things.



Update from Federal and Other Funding Agencies Plus
Thursday, May 28th: 9:30 a.m. – 11:30 a.m.



Ivan Montoya, M.D., M.P.H.

DHHS/National Institute on Drug Abuse

Dr. Montoya is the Director of the Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA), which is one of the institutes of the National Institutes of Health (NIH). He has a Medical Doctor and Psychiatrist degrees from the University of Antioquia in

Colombia, and a Master's in Public Health from Johns Hopkins University. He was a Fulbright-Humphrey Fellow at Johns Hopkins and Visiting Fellow at the Intramural Research Program 5 2024 ASCP Annual Meeting of NIDA. He joined NIDA's extramural program in 1999 as Medical Officer of the Clinical Trials Network, became the Deputy Director of DTMC in 2008 and the Director of DTMC in 2024. He has published extensively about treatments (pharmacological and non-pharmacological), and medical consequences of SUDs. He has received multiple awards including the NIH Director's Award and the Michael Morrison Award from CPDD. He is also Honorary Professor of the University of Valencia (Spain)



Daniel Falk, Ph.D.
NIAAA/NIH

Dr. Daniel Falk is the Branch Chief of the Medications Development Branch (MDB) within the Division of Treatment and Recovery (DTR) at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). At NIAAA, he directs research on pharmacotherapy for alcohol use disorder (AUD) and novel methods for clinical trials, including the evaluation of new endpoints. Dr. Falk

co-leads the NIAAA Alcohol Pharmacotherapy Evaluation Program (APEP) - a contract program which evaluates the efficacy and safety of novel and repurposed compounds to treat AUD in laboratory and randomized clinical trials. Dr. Falk is also the Coordinator of the NIAAA Data Archive, a large data repository over 400 NIAAA funded studies involving human subjects. Dr. Falk has authored a number of publications and presentations on a diverse set of alcohol-related topics, including pharmacotherapy to treat AUD, statistical methods and outcomes for alcohol clinical trials, psychiatric comorbidity of AUD, and correlates of alcohol use. Prior to joining NIAAA, he conducted epidemiologic research on AUD as a contractor for NIAAA. Dr. Falk received his Ph.D. in Clinical Psychology from the University of Miami.

**Lori Davis, M.D.**

Veterans Affairs Medical Center

Lori Davis, MD is Senior Research Psychiatrist at the Birmingham VA Health Care System and Adjunct Professor of Psychiatry in the Department of Psychiatry, University of Alabama Heersink School of Medicine, in Birmingham and Tuscaloosa, AL. She received her undergraduate degree from Duke University and her medical degree from the University of North Carolina at Chapel Hill. She completed a psychiatry residency at the University of Alabama at Birmingham. Dr. Davis served as Associate Chief of Staff for Research at the Tuscaloosa She was a member of the American Psychiatric Association Mood Disorders Workgroup on DSM-5 and the 2017 VA-DoD workgroup for the revision of the Clinical Practice Guidelines for PTSD. Dr. Davis has been designing and conducting clinical trials in mental health disorders for over 30 years under continuous peer-reviewed funding, resulting in over 120 publications. Her research aims to better understand the effects of pharmacotherapy, psychotherapy, vocational rehabilitation, mindfulness meditation, and other novel treatments for posttraumatic stress disorder (PTSD), depression, and substance use disorders.

**Fuad Issa, M.D.**

Defense Health Agency

Dr. Issa has been active in clinical research for 35 years. Since January 2022 he has been the Psychological Health Research Portfolio Manager at Research & Engineering Directorate, Defense Health Agency (DHA). Prior to that Dr. Issa served as Chief of Clinical Care at DHA Psychological Health Center of Excellence since 2016. He has worked in the civilian, military and veteran mental

health arenas both in clinical and research capacities. Dr. Issa has published in peer-reviewed journals, presented at national and international conferences, and authored book 10 2024 ASCP Annual Meeting chapters. Dr. Issa is board certified in Psychiatry, distinguished life fellow of the American Psychiatric Association, member of Society of Biological Psychiatry and American Medical Association. He is a Clinical Professor of Psychiatry and Behavioral Sciences at George Washington University.

**Yu-Ping (Tracy) Wang, M.D., M.Sc.**

Patient-Centered Outcomes Research Institute (PCORI)

Tracy Y. Wang, MD, MHS, MSc, is Chief of Comparative Clinical Effectiveness Research at the Patient-Centered Outcomes Research Institute (PCORI). She is a cardiologist and clinical researcher with expertise in observational research, implementation science, and pragmatic randomized clinical trials.



Wang leads PCORI's comparative effectiveness research portfolio focused on increasing the evidence base for existing interventions and emerging innovations to improve health outcomes and health equity through multidisciplinary research. She provides strategic guidance and oversight of ongoing programs and new initiatives designed to enhance and accelerate patient-centered comparative effectiveness research.

Prior to her current role, Wang was Professor of Medicine at Duke University and led several large studies at the Duke Clinical Research Institute that have focused on comparative effectiveness and safety, health disparities, care quality assessment, and quality improvement. To date, she has published over 350 peer-reviewed manuscripts, lectured widely on pragmatic trials and the use of data to guide initiatives aimed at reducing disparities in healthcare access and outcomes. Additionally, she has evolved the platform for research to diversify site and patient recruitment, innovate longitudinal patient follow-up, enrich the collection of patient-reported outcomes, and pragmatically adjudicate clinical events of interest. She previously served as Assistant Dean of Continuing Medical Education and Director of Health Services and Outcomes Research at Duke.

Wang has served on numerous volunteer committees, tasks forces, and writing groups for the American Heart Association, American College of Cardiology, and American College of Physicians. She previously chaired the AHA Council Operations Committee (2020-22) and AHA's Quality of Care and Outcomes Research (QCOR) Council (2017-19). She is an Associate Editor of the JAMA Internal Medicine journal and serves on the editorial boards of several other high-impact journals. In 2022, she was awarded the American Heart Association QCOR Outstanding Lifetime Achievement Award, and has received multiple awards recognizing her excellence in mentorship and leadership in enhancing diversity in both research participants and workforce.

An undergraduate of Yale University, Wang received her MD from Harvard Medical School, MSc in molecular biochemistry and biophysics from Yale University, and MHS in clinical research from Duke University.

**Matthew Rudorfer, M.D.**

National Institutes of Health/NIMH

Matthew Rudorfer, M.D. is Chief of the Psychopharmacology, Somatic, and Integrated Treatments Research Program in the National Institute of Mental Health (NIMH) Division of Services and Intervention Research (DSIR) Treatment and Preventive Interventions Research Branch. In this position Dr. Rudorfer provides programmatic support for

confirmatory efficacy and effectiveness clinical trials and related research focused on studies of optimized and personalized treatment across a range of disorders, mainly in adults, using a variety of medication, device-based, and behavioral interventions, often in sequence or combination. He also helps coordinate ethics research for the Institute. He has served as a member and chair of the FDA Psychiatric Drugs Advisory Committee.

Matt began his NIMH career in the intramural research program, where for several years he conducted research on novel and existing pharmacologic and neuromodulation treatments for complex mood disorders, establishing an ECT clinical and research service. Moving on to the extramural program, he served as program director of the annual NCDEU treatment research meeting – eventually co-chairing with ASCP – and editor-in-chief of the Psychopharmacology Bulletin before assuming his present position. Board-certified in Psychiatry and Clinical Pharmacology, Dr. Rudorfer received his medical degree from the State University of New York – Downstate Medical Center and trained in psychiatry at Washington University in St. Louis before coming to NIH. At present he maintains a small private practice of psychiatry and psychopharmacology and serves as chair of the Continuing Medical Education (CME) Committee of the Washington Psychiatric Society.



Plenary Panel: Artificial Intelligence: Understanding the Present and Anticipating the Future

Thursday, May 28th: 4:30 p.m. – 6:00 p.m.



John Torous, M.D., MBI

Beth Israel Deaconess Medical Center

Dr. John Torous, MD, MBI, is director of the digital psychiatry division in the Department of Psychiatry at Beth Israel Deaconess Medical Center (BIDMC), a Harvard Medical School-affiliated teaching hospital, where he also serves as a staff psychiatrist and associate professor. He has a background in electrical engineering and computer sciences and received an undergraduate degree in the field from UC

Berkeley before attending medical school at UC San Diego. He completed his psychiatry residency, fellowship in clinical informatics, and master's degree in biomedical informatics at Harvard. Dr. Torous is active in investigating the potential of mobile mental health and AI technologies for psychiatry, and his team supports mindapps.org as the largest database of mental health apps, mindApps.ai for benchmarking AI chatbots, mindLAMP technology platform for scalable digital phenotyping and interventions, and the Digital Navigator program to promote digital equity and access. Dr. Torous has published over 300 peer reviewed articles and 5 book chapters on the topic. He directs the Digital Psychiatry Clinic at BIDMC which seeks to improve access to and quality of mental health care through augmenting treatment with digital innovations. Dr. Torous serves as editor-in-chief for the journal JMIR Mental Health, web editor for JAMA Psychiatry, and a member of various American Psychiatric Association committees.

**Joseph Geraci, Ph.D.**

NetraMark Holdings

Dr. Joseph Geraci, Ph.D. is a mathematical physicist, medical scientist, and entrepreneur whose work focuses on the rigorous application of artificial intelligence to complex biomedical and clinical trial data. He is the Founder and Chief Scientific Officer/Chief Technology Officer of NetraMark Corp., where he leads the development of mathematically grounded AI methods designed specifically for small, heterogeneous clinical trial populations. In addition to his industry work, Dr. Geraci is an Assistant Professor of Molecular Medicine at Queen's University, with academic affiliations including the University of California, San Diego, Augusta University, and the Centre for Addiction and Mental Health (CAMH). He has collaborated with academic, regulatory, and industry partners on applications spanning psychiatry, oncology, and neurological disease, and has been recognized for advancing explainable, regulator-ready AI approaches that prioritize statistical validity, clinical relevance, and patient safety. Dr. Geraci's research sits at the intersection of high-dimensional statistics, machine learning, and translational medicine, with particular emphasis on patient stratification, treatment–placebo differentiation, and reproducible evidence generation in psychiatry and neuroscience. His work draws on foundational results from probability theory and information geometry to address known limitations of conventional machine learning approaches when applied to real-world clinical trial data. Dr. Geraci brings a pragmatic perspective to the use of AI in medicine, emphasizing both the promise of emerging technologies—such as large language models—and the mathematical and clinical constraints that must be respected to ensure reliable, ethical, and clinically meaningful outcomes.

**Yulin Hswen, ScD, MPH**

University of California - San Francisco

Dr. Yulin Hswen, ScD, MPH is an Associate Professor at the University of Maryland College Park and an epidemiologist and computational researcher specializing in artificial intelligence, and population health surveillance. She is an Associate Editor at JAMA and JAMA+ AI and has led international research using social media, search data, and multimodal AI to study depression, suicide risk, substance use, and technology related mental health harms. Her work focuses on integrating ethical AI methods into public health practice to improve early detection, prevention, and health equity.

Regulatory Challenges: Ask the Experts

Friday, May 29th: 10:30 a.m. – 11:30 a.m.

**Tiffany Farchione, M.D.**

US Food and Drug Administration

Dr. Tiffany Farchione, M.D. received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, Dr. Farchione was affiliated with the University of Pittsburgh Medical Center and was on the faculty of the University of Pittsburgh. As the Director of the Division of Psychiatry at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development



activities conducted under investigational new drug applications, and the review of all new drug applications and supplements for new psychiatric drug claims.



Valentina Mantua, M.D., Ph.D.

Center for Drug Evaluation and Research,
Food and Drug

Dr. Valentina Mantua, M.D., Ph.D., is Associate Director for Regulatory Science in the Office of Neuroscience at FDA's Center for Drug Evaluation and Research (CDER). She leads initiatives to advance innovative methods and tools in clinical trials and represents the Agency in pre-competitive collaborations with partners including NIH and

FNIH. Before joining FDA in 2019, Dr. Mantua served as a delegate of the Italian Medicines Agency (AIFA) to several committees and working parties of the European Medicines Agency (EMA) and practiced as a board-certified psychiatrist in the UK at South London and Maudsley NHS Foundation Trust. She is an active committee member of the American Society of Clinical Psychopharmacology (ASCP). Dr. Mantua received her M.D. and psychiatry residency training from Sapienza University of Rome and a Ph.D. in Neurobiology of Affective Disorders from the University of Pisa.



Bernard Fischer, M.D.

U.S. Food and Drug Administration

Dr. Bernard Fischer, M.D. is a psychiatrist and the acting Deputy Director of the Office of Neuroscience in the Office of New Drugs at the U.S. Food and Drug Administration (FDA). He provides regulatory oversight of development and marketing approval of drugs for psychiatric



and neurologic disorders, addiction, anesthesia, and pain under investigational new drug applications (INDs) and new drug applications (NDAs). Prior to the FDA, he spent more than 10 years in academic medicine at the Maryland Psychiatric Research Center (MPRC) and the Department of Veterans Affairs. Dr. Fischer earned his medical degree from the Medical College of Virginia. He completed a 5-year research/clinical residency in psychiatry at the University of Maryland/Sheppard Pratt followed by a post-doctoral fellowship in mental illness research at the MPRC. He holds a master's degree in biomedical ethics and has been board certified in both psychiatry and addiction medicine. He has authored or co-authored more than 50 scientific publications.



Acknowledgements

Program Committee for the Annual Meeting (PCAN) Chairs



Tiffany Farchione, M.D.



Carlos Blanco, M.D.

Review Sub-Committee Chairs



Manish Jha, M.D.



Dan Iosifescu, M.D., M.Sc



New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Ivan Montoya, M.D., Ph.D.

Program Committee for the Annual Meeting and Review Subcommittee Members

Scott Aaronson, M.D. *
Sheppard Pratt

Saeed Ahmed, M.D.
Saint Francis Hospital and
Medical Center, Trinity Health of
New England

Carlos Blanco, M.D.
National Institute on Drug Abuse

Leslie Citrome, M.D., M.P.H.
New York Medical College

Lawrence Cohen, B.A.,
Pharm.D.
UNT System College of
Pharmacy/ Regulatory Insurance
Advisors

M. Crismon, Pharm.D.
The University of Texas at
Austin

Justin Faden, D.O.
Rowan University

★ Tiffany Farchione, M.D.
US Food and Drug
Administration

Marlene Freeman, M.D.
Massachusetts General Hospital,
Ammon-Pinizzotto Center for
Women's Mental Health

Ahmad Hameed, M.D.
Penn State College of Medicine



★ Rebecca Hendrickson, M.D.,
Ph.D.
VA Puget Sound Health Care
System

Michael Henry, M.D.
Massachusetts General Hospital

★ Dan Iosifescu, M.D., M.Sc.
New York University School of
Medicine

★ Manish Jha, M.D.
University of Texas
Southwestern Medical Center

★ Jordan Karp, M.D.
University of Arizona College of
Medicine

Susan Kornstein, M.D.
Virginia Commonwealth
University

Valentina Mantua, M.D.
Center for Drug Evaluation and
Research, Food and Drug
Administration

★ Matej Markota, M.D.
Mayo Clinic

★ Nicholas Murphy, Ph.D.
Texas A&M University, Naresh
K. Vashisht College of Medicine

★ Carla Nasca, Ph.D.
NYU Langone Department of
Psychiatry

Luca Pani, M.D. *
University of Miami

Gerard Sanacora, M.D., Ph.D.
Yale

★ Manpreet Singh, M.D., M.S.
University of California, Davis,
School of Medicine

★ Jair Soares, M.D., Ph.D.
University of Texas School of
Medicine at Houston

Louisa Steinberg, M.D.
ICON Plc

Oleg Tcheremissine, M.D.
Atrium Health

Antonio Teixeira, M.D.
University of Texas Health
Science Center at San Antonio

Ottavio Vitolo, M.D.
Cerevance

Eric Wexler, M.D., Ph.D.
Modernbrains

★ Carlos Zarate, M.D.
National Institute of Mental
Health



★ Zachary Zuschlag, D.O.
James A. Haley Veterans Hospital

New Investigator Award Program Committee

★ Mahavir Agarwal, M.D.,
Ph.D.
Centre for Addiction and Mental
Health (CAMH), Canada

★ Elizabeth Ballard, Ph.D.
National Institute of Mental
Health

★ Lori Davis, M.D.
Veterans Affairs Medical Center

★ Walter Dunn, M.D., Ph.D.
West Los Angeles VA Medical
Center/UCLA

Daniel Falk, Ph.D.
NIAAA/NIA

★ Tiffany Farchione, M.D.
US Food and Drug
Administration

Margaret Grabb, Ph.D.
National Institute of Mental
Health

Bruce Kinon, M.D.
MycoMedica Life Sciences

Ivan Montoya, M.D., M.P.H.
DHHS/National Institute on
Drug Abuse

★ Katharine Phillips, M.D.
Weill Cornell Medical College
and New York
Presbyterian/Weill Cornell
Medical Center

Mark Rapaport, M.D.
American Psychiatric
Association

Nina Schooler, Ph.D.
SUNY Downstate Health
Sciences Center

★ Holly Swartz, M.D.
University of Pittsburgh School
of Medicine



ASCP Officers and Board

★ Anita H. Clayton, M.D.
President
University of Virginia

★ Carlos Zarate, M.D.
President-Elect
National Institute of Mental
Health

★ Joseph F. Goldberg, M.D.
Past President
Icahn School of Medicine at
Mount Sinai

★ Dan Iosifescu, M.D.
Treasurer
New York University School of
Medicine

Matthew Macaluso, D.O.
Treasurer-Elect
The University of Alabama at
Birmingham

★ Holly Swartz, M.D.
Past-Treasurer
University of Pittsburgh School
of Medicine

Scott Aaronson, M.D.
Sheppard Pratt

Alexandra Aaronson, M.D.,
M.Sc.
Edward Hines VA Hospital

Elizabeth Ballard, Ph.D.
National Institute of Mental
Health

★ Crystal Clark, M.D.
University of Toronto, Women's
College Hospital

Marlene Freeman, M.D.
Editor, *The Journal of Clinical
Psychiatry*
Massachusetts General Hospital,
Ammon-Pinizzotto Center for
Women's Mental Health

★ Manish Jha, M.D.
University of Texas
Southwestern Medical Center
Susan Kornstein, M.D.
Virginia Commonwealth
University

Sanjay Matthew, M.D.
Baylor College of Medicine

Andrew Nierenberg, M.D.
Massachusetts General Hospital

★ George Papakostas, M.D.
Massachusetts General Hospital

Gerard Sanacora, M.D., Ph.D.
Yale University

★ Erika Saunders, M.D.
Penn State College of Medicine,
Penn State Health

**★New Investigator Alumni****Meeting Announcements****Registration Desk* Hours:**

Monday	1:00 p.m. – 6:00 p.m.
Tuesday	7:30 a.m. – 6:00 p.m.
Wednesday	7:30 a.m. – 7:00 p.m.
Thursday	6:30 a.m. – 6:00 p.m.
Friday	7:30 a.m. – 10:30 a.m.

*The registration/meeting information desk is located in the Rotunda East – Second Level of the Loews Miami Beach Hotel.

Speaker Ready Room* Hours:

Monday	1:00 p.m. - 5:00 p.m.
Tuesday	7:30 a.m. - 6:00 p.m.
Wednesday	7:30 a.m. – 6:00 p.m.
Thursday	7:30 a.m. – 6:00 p.m.
Friday	7:30 a.m. - 10:00 a.m.

*The Speaker Ready Room is located in the New Yorker Room at the Loews Miami Beach Hotel.

The meeting organizers ask that all speakers upload their slides no later than 24 hours prior to their scheduled presentation time.

ASCP Wi-Fi

SSID: ASCP2026

Access Code: ASCP2026

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascp.org.



Discounts – All ASCP meeting attendees who booked their room at the Loews Miami Beach Hotel through the ASCP website will have the following resort amenities.

- Complimentary basic wireless internet in all guest rooms
- Fitness Center admittance

ASCP Membership - If you would like to join ASCP, you can log onto our website at <https://ascpp.org/members/join-form/> and register online. Membership applications are available at the ASCP registration desk, located in the Rotunda East - Second Level. You may also contact the ASCP office at 615-649-3085 to request one.



Continuing Education Credits

Continuing Education Credits are available for physicians, pharmacists, and psychologists. **Self-assessment maintenance of certification credits** are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed during or after the meeting at www.ASCPMeeting.org. *Surveys for continuing education credit must be submitted no later than Tuesday, July 01, 2026.*

There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

The American Board of Psychiatry and Neurology has reviewed the annual meeting and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Live Continuing Education

American Society of Clinical Psychopharmacology
2026 ASCP Annual Meeting
May 26 - 29, 2026 Miami, FL

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Society of Clinical Psychopharmacology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the



Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of 21.00 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 21.00 knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurses

Amedco LLC designates this activity for a maximum of 21.00 ANCC contact hours.

Psychologists



This course is co-sponsored by Amedco and American Society of Clinical Psychopharmacology. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and content. Maximum of 21.00 hours.

The following state boards accept courses from APA providers for Psychologists/Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID,



IL, IN, KS, KY, MA, ME, MN, MO, NC, ND, NH, NE, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WY*

MA: Accepts APA for all classes of psychology license; does not accept APA for licensed counselors (LMHC, LMFT, etc.) except LEP.

MD: Does not accept Jointly Accredited content.

MI: Accepts courses from APA for Psychologists. No general CE requirement for Counselors.

OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY*

AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

MI MFTs: There are no CE requirements for MFTs in MI.

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY ONLY), OK, OR, SC, UT, WA, WI, WY*

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

New York Psychologists

Amedco is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. 21.00 hours.



Thank you to our Sponsors for their support.

Platinum



Gold



Silver





2027 ASCP Annual Meeting

Save the Date



The 2027 ASCP Annual Meeting will take place June 1 - June 4, 2027, at the Chicago Marriott Downtown Magnificent Mile in Chicago, Illinois. Details regarding abstract submission for the 2027 Annual Meeting will be released in September 2026.



9:00 a.m. - 10:30 a.m.	Panel Sessions
------------------------	----------------

9:00 a.m. - 10:30 a.m.

***Novel Therapeutics With Entactogenic Effects - A New Frontier for Mood and Anxiety Disorders?**

Americana 1

Chair: Hiroe Hu, National Institute of Mental Health

9:09 a.m. - 9:27 a.m.

EMP-01 (R-MDMA) as a Next-Generation Entactogen: Mechanistic Rationale and Therapeutic Potential in Social Anxiety Disorder

Sarah McEwen, Atai Beckley

9:27 a.m. - 9:45 a.m.

Intravenous Ketamine Improves Social Anhedonia in Patients With Treatment-Resistant Depression and Suicidal Ideation

Hiroe Hu, National Institute of Mental Health

9:45 a.m. - 10:03 a.m.

Ketamine's Potential for Treating Loneliness in Treatment Resistant Bipolar Depression

Diana Orsini, University of Toronto

10:03 a.m. - 10:21 a.m.

Objective Measures of Empathy: Prosocial Learning and Mood States

Yoojin Lee, National Institute of Mental Health, National Institutes of Health

Discussant: James Murrough, Icahn School of Medicine at Mount Sinai

9:00 a.m. - 10:30 a.m.

***Targeted Interventions for Suicide Prevention**

Americana 2

Chair: Jill Harkavy-Friedman, American Foundation for Suicide Prevention

Co-Chair: Elizabeth Ballard, National Institute of Mental Health

9:09 a.m. - 9:27 a.m.

Using Intensive, Real-Time Monitoring Designs to Identify Proximal Risk Factors for Suicidal Ideation Among Adolescents

Jessica Hamilton, Rutgers University, Department of Psychology

9:27 a.m. - 9:45 a.m.

Changes in Symptoms of Suicidal Ideation and Related Symptoms with Tirzepatide in Individuals with Moderate-To-Severe Methamphetamine Use Disorder

Snoben Kuruvila, UTSW Medical Center Dallas

9:45 a.m. - 10:03 a.m.

Psychosocial Interventions for Older Adults with Depression and Varying Degrees of Cognitive Functioning after a Suicide-Related Hospitalization

Dimitris Kiosses, Weill Cornell Medical College

10:03 a.m. - 10:21 a.m.



Efficacy and Safety of a Single Dose of Psilocybin for Chronic Active Suicidal Ideation: Experiences in an Open Label Trial

Scott Aaronson, Sheppard Pratt

Discussant: Jill Harkavy-Friedman, American Foundation for Suicide Prevention

9:00 a.m. - 10:30 a.m.

***Conducting Clinical Trials Using Combined Treatment Modalities: Challenges, Opportunities, and Insights for Future Regulatory Consideration**

Poinciana 1 and 2

Chair: Samuel Wilkinson, Yale School of Medicine

Co-Chair: Gerard Sanacora, Yale University, New Haven, CT, USA

9:09 a.m. - 9:33 a.m.

Cognitive Behavioral Therapy following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-Endure Study

Samuel Wilkinson, Yale School of Medicine

9:33 a.m. - 9:57 a.m.

Interim Data From a Randomized Placebo-Controlled Trial of Accelerated Transcranial Magnetic Intermittent Theta-Burst Stimulation and Adjunctive D-Cycloserine for Suicidal Ideation

Alexander McGirr, University of Calgary, Dept. of Psychiatry

9:57 a.m. - 10:21 a.m.

Synergistic Biobehavioral Treatments to Reduce Depression and Compulsivity

Shabnam Hossein, University of Pittsburgh

Discussant: Zimri Yaseen, FDA/CDER/OND/ON/DP

9:00 a.m. - 10:30 a.m.

***Novel Targets and Treatments for Stimulant Use Disorders and Depression**

Poinciana 3 and 4

Chair: Keren Bachi, The Addiction Institute of Mount Sinai; Icahn School of Medicine at Mount Sinai

Co-Chair: Rana Jawish, University of Utah School of Medicine

9:09 a.m. - 9:27 a.m.

Social-Neurobehavioral Phenotypes for Advancement of Social-Target Intervention in Cocaine Use Disorder

Keren Bachi, The Addiction Institute of Mount Sinai; Icahn School of Medicine at Mount Sinai

9:27 a.m. - 9:45 a.m.

Feasibility and Preliminary Efficacy of Tirzepatide for Individuals with Moderate/Severe Methamphetamine Use Disorder

Manish Jha, University of Texas Southwestern Medical Center

9:45 a.m. - 10:03 a.m.

Accelerated Course of Intermittent Theta Burst for Methamphetamine Use Disorder: Feasibility and EEG-Derived Functional Connectivity Correlates of Treatment Response

Nabila Haque, University of Texas Southwestern Medical Center



10:03 a.m. - 10:21 a.m. **Integrating Cognitive-Behavioral Therapy with Repetitive Transcranial Magnetic Stimulation (CBT/TMS): A Novel Combined Neuromodulation-Psychotherapy Model for Prenatal Depression**

Rana Jawish, University of Utah School of Medicine

Discussant: Rong Xu, Case Western Reserve University

11:00 a.m. - 12:30 p.m.	Panel Sessions
-------------------------	----------------

11:00 a.m. - 12:30 p.m.

***Strategies to Improve Treatment Effect Detection in MDD Trials**

Americana 1

Chair: George Papakostas, Massachusetts General Hospital

11:09 a.m. - 11:33 a.m.

Strategies to Improve Treatment Effect Detection in MDD Trials

Clotilde Guidetti, Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School

11:33 a.m. - 11:57 a.m.

Functional Connectivity of the Striatum as a Biomarker of Treatment Response to KCNQ-Targeted Agents in Depression

James Murrough, Icahn School of Medicine at Mount Sinai

11:57 a.m. - 12:21 p.m.

Depression and Disturbances in Circadian Rhythms: Pathways for Novel Treatment Development

Emmanuel Mignot, Stanford University School of Medicine, Department of Psychiatry

Discussant: Manish Jha, University of Texas Southwestern Medical Center

11:00 a.m. - 12:30 p.m.

Speed Kills: Why CNS Clinical Trials Fail and How to Protect Signal, Patients, and Programs

Americana 2

Chair: Tom Zoda, Cognitive Research Corporation

11:09 a.m. - 11:33 a.m.

Speed Kills: Why CNS Clinical Trials Fail and How to Protect Signal, Patients, and Programs

Stephen Brannan, CNS Clinical Consulting LLC

11:33 a.m. - 11:57 a.m.

Speed Kills: A Site Perspective on Success and Failure in Clinical Trials

David Walling, CenExel - CNS

11:57 a.m. - 12:21 p.m.

Speed Kills: Why CNS Clinical Trials Fail and How to Protect Signal, Patients, and Programs



Patrick Harrington, EMA Wellness

Discussant: Alexandria Wise, Syneos Health

11:00 a.m. - 12:30 p.m.

***Improving Metabolic Health in Mental Illness: A Transdiagnostic Approach**

Poinciana 1 and 2

Chair: Mahavir Agarwal, Centre for Addiction and Mental Health

Co-Chair: Benjamin Perry, University of Birmingham

11:09 a.m. - 11:33 a.m.

Psymetric 2.0: Development, Refinement and External Validation of Clinic-Ready Cardiometabolic Prediction Models for Young People with Psychosis Spectrum Disorders

Benjamin Perry, University of Birmingham

11:33 a.m. - 11:57 a.m.

Treating Psychotropic Associated Weight Gain in Individuals with Intellectual and Developmental Disability: A Retrospective Chart Review Study

Nicolette Stogios, Centre for Addiction and Mental Health, University of Toronto

11:57 a.m. - 12:21 p.m.

PTSD and Diabetes: A Two-Way Street in Metabolic and Mental Health

Katharine Liang, VA Puget Sound Health Care System

Discussant: Rebecca Hendrickson, VA Puget Sound Health Care System

11:00 a.m. - 12:30 p.m.

^Towards an International, Standardized Model Psychopharmacology Curriculum for Psychiatry Residency Training: A Competency-Based Framework for Implementation

Poinciana 3 and 4

Chair: Matthew Macaluso, The University of Alabama At Birmingham

Co-Chair: Anita Clayton, University of Virginia SOM

11:09 a.m. - 11:33 a.m.

The ASCP Model Psychopharmacology Curriculum update

Richard Shelton, University of Alabama At Birmingham

11:33 a.m. - 11:57 a.m.

Towards an International, Standardized Model Psychopharmacology Curriculum for Psychiatry Residency Training: A Competency-Based Framework for Implementation

Gemma Espejo, University of California, Irvine School of Medicine

11:57 a.m. - 12:21 p.m.

Towards an International, Standardized Model Psychopharmacology Curriculum for Psychiatry Residency Training: A Competency-Based Framework for Implementation

Keanna Lee, edYOU Technologies

Discussant: Joseph Goldberg, Icahn School of Medicine at Mount Sinai



2:00 p.m. - 4:00 p.m.	Pharmaceutical Pipeline Session
-----------------------	---------------------------------

Americana 3

2:00 p.m. - 2:10 p.m.

RE104: A Novel Serotonergic Psychedelic 4-OH-DiPT Prodrug for the Treatment of Postpartum Depression

Mark Pollack, Reunion Neuroscience

2:10 p.m. - 2:20 p.m.

A New Dawn for Social Anxiety Treatment: Clinical Advancement of the Novel V1aR Antagonist, NTX-1472

Tiffany Lago, Newleos Therapeutics

2:20 p.m. - 2:30 p.m.

DT-101 – a Novel alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Receptor (AMPA) Positive Allosteric Modulator Demonstrates Favorable Tolerability and Functional Biomarkers in Phase 1 Healthy Volunteer Trial

Simon Ward, Draig Therapeutics

2:30 p.m. - 2:40 p.m.

Seltorexant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder With Insomnia Symptoms: Phase 3 Studies

Gahan Pandina, Johnson and Johnson, Titusville, NJ, USA

2:40 p.m. - 2:50 p.m.

Ketamine Treatment for Non-Motor Symptoms of Parkinson's Disease

Gerard Sanacora, Yale University, New Haven, CT, USA

2:50 p.m. - 3:00 p.m.

Forvisirvat (SP-624), a First-In-Human SIRT6 Activator with an Epigenetic Mechanism of Action, Currently in a Phase 2b-3 Study for the Treatment of Major Depressive Disorder.

Joel Raskin, Sirtsei Pharmaceuticals

3:00 p.m. - 3:10 p.m.

Unlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-Targeting Prodrug Technology

Sergey Yagoda, Seaport Therapeutics

3:10 p.m. - 3:20 p.m.

BH-200 (nelivaptan), a Vasopressin V1b Receptor Antagonist, in Genetically Defined Subgroups of MDD: Precision Targeting of Hpa-Axis Dysregulation in the Olive Phase 2 Program

Hans Eriksson, HMNC Brain Health

3:20 p.m. - 3:30 p.m.

Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of Lpcn 1154A

Anthony DelConte, Lipocine



3:30 p.m. - 3:40 p.m.

A Randomized, Placebo-Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Rodrigo Machado-Vieira, McGovern Medical School, University of Texas Science Center in Houston

3:40 p.m. - 3:50 p.m.

Prospective Replication of an Eeg Biomarker for Predicting Changes in Attention in ALTO-203, an H3 Inverse Agonist

Adam Savitz, Alto Neuroscience

4:15 p.m. - 6:15 p.m.	Workshops
-----------------------	-----------

4:15 p.m. - 6:15 p.m.

***Deploying Artificial Intelligence (AI) and Large Language Models (LLMs) in Psychiatry Drug Development**

Americana 1

Chair: Daniel Karlin, MD, MA, Mind Medicine Inc., Tufts University School of Medicine

4:24 p.m. - 4:48 p.m.

Deploying Artificial Intelligence (AI) and Large Language Models (LLMs) in Psychiatry Drug Development

Todd Solomon, Mind Medicine Inc.

4:48 p.m. - 5:12 p.m.

Deploying Artificial Intelligence (AI) and Large Language Models (LLMs) in Psychiatry Drug Development

Anzar Abbas, Brooklyn Health

5:12 p.m. - 5:36 p.m.

Deploying Artificial Intelligence (AI) and Large Language Models (LLMs) in Psychiatry Drug Development

Michelle Worthington, Brooklyn Health

5:36 p.m. - 6:00 p.m.

Deploying Artificial Intelligence (AI) and Large Language Models (LLMs) in Psychiatry Drug Development

Isaac Galatzer-Levy, Google

Discussant: Isaac Galatzer-Levy, Google

4:15 p.m. - 6:15 p.m.

***Designing the Next Generation of Studies of Psychedelics for Difficult to Treat Depression**

Americana 2

Chair: Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenzo VAMC



4:25 p.m. - 4:55 p.m.

Using Neuroimaging to Elucidate Psychedelic Mechanisms of Action on Brain Circuits
Yvette Sheline, University of Pennsylvania

4:55 p.m. - 5:25 p.m.

Long Term Outcomes from Psilocybin and Response to Re-Dosing for Difficult to Treat Depression
Trisha Suppes, Stanford University

5:25 p.m. - 5:55 p.m.

Critical Methodological Decisions in Psychedelic Drug Trials
Maurizio Fava, Massachusetts General Hospital

4:15 p.m. - 6:15 p.m.

***Findings From the ASCP Presidential Task Force on Psychotropic Drug Polypharmacotherapy**
Poinciana 1 and 2

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

Co-Chair: Nassir Ghaemi, Tufts University/Harvard Medical School

4:25 p.m. - 4:42 p.m.

Underutilized Augmenters in Polypharmacy Regimens: The Case for Lithium
Nassir Ghaemi, Tufts University/Harvard Medical School

4:42 p.m. - 4:59 p.m.

Rational and Irrational Psychopharmacology Combinations
Joseph Goldberg, Icahn School of Medicine at Mount Sinai

4:59 p.m. - 5:16 p.m.

When to Switch Versus Augment Pharmacotherapies
Snoben Kuruvila, UTSW Medical Center Dallas

5:16 p.m. - 5:33 p.m.

Mondo Combo: Do Combinations of Antipsychotics Ever Make Any Sense?
Leslie Citrome, New York Medical College

5:33 p.m. - 5:50 p.m.

Comorbidity Polypharmacy: Simultaneous vs. Successive Introduction of Co-Pharmacotherapies
Anita Clayton, University of Virginia SOM

5:50 p.m. - 6:07 p.m.

Safety, Tolerability, and Drug-Drug Interaction Concerns in Polypharmacology Regimens
Rajnish Mago, Simple and Practical Medical Education, LLC



4:15 p.m. - 6:15 p.m.

***^Waking up to Excessive Daytime Sleepiness in Psychiatry and How to Make Wearables Work for Measuring Sleep and Activity**

Poinciana 3 and 4

Chair: Manish Jha, University of Texas Southwestern Medical Center

Co-Chair: Jean Marrero-Polanco, Mayo Clinic

4:25 p.m. - 4:50 p.m.

Sleep Assessments as Predictors of Health Risk and Depression

Emmanuel Mignot, Stanford University School of Medicine, Department of Psychiatry

4:50 p.m. - 5:15 p.m.

Smartwatch Measurements and Controlled Depression: Comparative Analyses on Physical Activity and Sleep

Arjun Athreya, Mayo Clinic

5:15 p.m. - 5:40 p.m.

Sleep and its Utility for Mental Health and Well-Being Research: The Case for Longitudinal Measurements

Milica Barac, Mayo Clinic

Discussant: William Bobo, Florida State University



8:30 a.m. - 10:00 a.m.	Regulatory Plenary
------------------------	--------------------

Americana 3

8:30 a.m. - 10:00 a.m.

Regulatory Plenary: AI-Based Tools in CNS Drug Development: A Regulatory Framework for Clinical Trial Applications

Americana 3

Chair: Tiffany Farchione, US Food and Drug Administration

8:40 a.m. - 9:00 a.m.

Regulatory Plenary: AI-Based Tools in CNS Drug Development: A Regulatory Framework for Clinical Trial Applications

Valentina Mantua, Center for Drug Evaluation and Research, Food and Drug Administration

9:00 a.m. - 9:20 a.m.

Regulatory Plenary: AI-Based Tools in Cns Drug Development: A Regulatory Framework for Clinical Trial Applications

Qi Liu, Center for Drug Evaluation and Research, Food and Drug Administration

9:20 a.m. - 9:40 a.m.

Regulatory Plenary: AI-Based Tools in CNS Drug Development: A Regulatory Framework for Clinical Trial Applications

Bernard Fischer, U.S. Food and Drug Administration

9:40 a.m. - 10:00 a.m.

Regulatory Plenary: AI-Based Tools in CNS Drug Development: A Regulatory Framework for Clinical Trial Applications

Roberta Rasetti, FDA/CDER/DP

10:15 a.m. - 11:45 a.m.	ASCP Awards Ceremony
-------------------------	----------------------

Americana 3

10:15 a.m. - 11:45 a.m.

ASCP Lifetime Awardee Talk and Nasrallah Awardee

Americana 3

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

Co-Chair: Anita Clayton, University of Virginia SOM

10:25 a.m. - 10:55 a.m.

The Tyranny of the P-value: Effect Size Matters

Leslie Citrome, New York Medical College

10:55 a.m. - 11:25 a.m.

A Short Journey Through a 50 Years of Progress in the Treatment of Depression



Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenzo VAMC

1:30 p.m. - 3:00 p.m.	Clinical Updates on Neurotherapeutics
-----------------------	--

Americana 3

1:30 p.m. - 3:00 p.m.

Clinical Updates on Neurotherapeutics: Disease State

Americana 3

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

Co-Chair: David Liebers, New York University School of Medicine

1:35 p.m. - 1:54 p.m.

SGAs vs Mood Stabilizers: The Paradigm Shift in Core Treatment for Bipolar Disorder

Joseph Goldberg, Icahn School of Medicine at Mount Sinai

1:54 p.m. - 2:13 p.m.

An Update on Bipolar Disorder: Evidence, Challenges, and Solutions

Andrew Nierenberg, Massachusetts General Hospital

2:13 p.m. - 2:32 p.m.

The Pharmacologic Treatment of Schizophrenia: Status Report

John Kane, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

2:32 p.m. - 2:51 p.m.

Exciting New Findings From Clinical Trials in the Treatment of Post-Traumatic Stress Disorder

Lori Davis, Veterans Affairs Medical Center

3:15 p.m. - 4:45 p.m.	Individual Research Reports (IRRs)
-----------------------	---

3:15 p.m. - 4:45 p.m.

Individual Research Reports (IRRs) 1: Psychosis, Sleep, and Learning

Americana 1

Chair: Amit Anand, MD

3:15 p.m. - 3:35 p.m.

Schizophrenia Polygenic Risk is Negatively Associated With Body Mass Index in Two Population Cohorts

Olaoluwa Okusaga, Michael E DeBakey VA Medical Center/Baylor College of Medicine

3:35 p.m. - 3:55 p.m.

Retrospective Analysis of Real-World Transition Strategies for Xanomeline and Trospium Chloride in Adult Patients With Schizophrenia

Jenna Hoogerheyde, Bristol-Myers Squibb

3:55 p.m. - 4:15 p.m.



Sleep Estimation From Low-Frequency Smartphone Sensors via Bayesian Hidden Markov Model

Jin Soo Byun, Harvard Medical School/BIDMC

4:15 p.m. - 4:35 p.m.

Neural and Behavioral Evidence From Reinforcement Learning Converge in Support of Relaxed Beliefs Under LSD

Jonathan Kanen, Icahn School of Medicine At Mount Sinai

3:15 p.m. - 4:45 p.m.

Individual Research Reports (IRRs) 2: Stimulant Medications and Drugs

Americana 2

Chair: Rebecca Hendrickson, MD, PhD

3:15 p.m. - 3:35 p.m.

Augmenting Dorsolateral Prefrontal Cortex-Targeted TDCS With Cognitive Reappraisal in Cocaine Use Disorder

Yuefeng Huang, Icahn School of Medicine At Mount Sinai

3:35 p.m. - 3:55 p.m.

Mixed Amphetamine Salts and Lisdexamfetamine as Adjunctive Treatment for Bipolar Depression: Pooled Analysis of Two Randomized Controlled Trials

Mark Frye, Mayo Clinic

3:55 p.m. - 4:15 p.m.

Brain-to-Brain Movie Neurofeedback Reduces Craving in Opioid Use Disorder

Natalie McClain, Icahn School of Medicine At Mount Sinai

4:15 p.m. - 4:35 p.m.

ASCP Task Force on Deprescribing Stimulants for ADHD in Adults

David Goodman, Johns Hopkins School of Medicine

3:15 p.m. - 4:45 p.m.

Individual Research Reports (IRRs) 3: Glutamate Modulators

Poinciana 1 and 2

Chair: Sanjay Mathew, MD

3:15 p.m. - 3:35 p.m.

Evaluating Hepatic Effects of Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression

Gabrielle Lovell, University of Toronto

3:35 p.m. - 3:55 p.m.

Drug Liking and Craving of Intravenous Ketamine When Prescribed for the Treatment of Mood Disorders in a Monitored Setting: A Descriptive Analysis

Shreya Vasudeva, University of Toronto

3:55 p.m. - 4:15 p.m.

Combined Ketamine and Cognitive Behavioral Therapy: Leveraging Metaplasticity to Enhance Outcomes

Songjun Li, Yale

4:15 p.m. - 4:35 p.m.



Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized, Midazolam-Controlled Clinical Trial

Diana Orsini, University of Toronto

3:15 p.m. - 4:45 p.m.

Individual Research Reports (IRRs) 4: Depression and PTSD

Poinciana 3 and 4

Chair: Dan Iosifescu, MD

3:15 p.m. - 3:35 p.m.

AMPA Receptor Binding Potential is Reduced in the Anterior Cingulate Cortex of Female Patients with PTSD

Nicholas Murphy, Texas A&M University, Naresh K. Vashisht College of Medicine

3:35 p.m. - 3:55 p.m.

Durability of TMS Treatment for Veterans With MDD Examined via Significant Psychiatric Events Associated With Relapse (SPEAR): A Proposed New Composite Outcome Measure for High Severity/Low Frequency Mental Health Events

Zachary Zuschlag, James A. Haley Veterans Hospital

3:55 p.m. - 4:15 p.m.

Is Brain Insulin Action Implicated in the Biology of Depression? A Pilot Neuroimaging Study in Adolescents

Kateryna Maksyutynska, Centre for Addiction and Mental Health (CAMH)

4:15 p.m. - 4:35 p.m.

Semaglutide Improves Health-Related Quality of Life in Major Depressive Disorder Independent of Mood Change: Evidence for Metabolic and Motivational Pathways

Cristian-Daniel Llach Lopez, University of Toronto

7:00 p.m. - 8:30 p.m.	Satellite Symposium
-----------------------	---------------------

Americana 1

7:00 p.m. - 8:30 p.m.

Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders

Americana 1

Chair: Emmanuel Mignot, Stanford University School of Medicine, Department of Psychiatry

7:10 p.m. - 8:30 p.m.

Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders

Roger McIntyre, University of Toronto

7:10 p.m. - 8:30 p.m.

Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders

Emmanuel Mignot, Stanford University School of Medicine, Department of Psychiatry



6:30 a.m. - 8:00 a.m.	Satellite Symposium
-----------------------	---------------------

Americana 1

6:30 a.m. - 8:00 a.m.

**Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice:
Overcoming Clinical Inertia**

Americana 1

Chair: Jose Rubio, Northwell Health

6:40 a.m. - 7:05 a.m.

**Incorporating Novel Muscarinic Agents for Schizophrenia into Clinical Practice:
Overcoming Clinical Inertia**

Jose Rubio, Northwell Health

7:05 a.m. - 7:30 a.m.

**Incorporating Novel Muscarinic Agents for Schizophrenia into Clinical Practice:
Overcoming Clinical Inertia**

Sunny Tang, Zucker School of Medicine at Hofstra/Northwell

7:30 a.m. - 7:55 a.m.

**Incorporating Novel Muscarinic Agents for Schizophrenia into Clinical Practice:
Overcoming Clinical Inertia**

Megan Good, Beth Israel Deaconess Medical Center

8:15 a.m. - 9:15 a.m.	Keynote Plenary
-----------------------	-----------------

Americana 3

8:15 a.m. - 9:15 a.m.

AI Beyond Evil Robots: Ensuring Transformative Means Better

Americana 3

Chair: Tiffany Farchione, US Food and Drug Administration

8:25 a.m. - 9:15 a.m.

AI Beyond Evil Robots: Ensuring Transformative Means Better

Roy Perlis, Massachusetts General Hospital

9:30 a.m. - 11:30 a.m.	Update from Federal and Other Funding Agencies Plenary
------------------------	---

Americana 3

9:30 a.m. - 11:30 a.m.

Update From Federal and Other Funding Agencies

Americana 3

Chair: Anita Clayton, University of Virginia SOM



Co-Chair: Katharine Liang, VA Puget Sound Health Care System

9:35 a.m. - 9:52 a.m.

NIAAA Update: Focus on the Medications Development Program

Daniel Falk, NIAAA/NIH

9:52 a.m. - 10:09 a.m.

Patient-Centered Comparative Effectiveness Research

Yu-Ping Wang, Patient-Centered Outcomes Research Institute (PCORI)

10:09 a.m. - 10:26 a.m.

Advancing Therapeutics for Substance Use Disorders Through NIDA's Therapeutics Development Program

Ivan Montoya, DHHS/National Institute on Drug Abuse

10:26 a.m. - 10:43 a.m.

Update From Defense Health Agency Psychological Health Research Portfolio

Fuad Issa, Defense Health Agency

10:43 a.m. - 11:00 a.m.

Updates From Veteran Health Administration (VA) Research Initiatives

Lori Davis, Veterans Affairs Medical Center

11:00 a.m. - 11:17 a.m.

NIMH Update

Matthew Rudorfer, National Institutes of Health/NIMH

1:15 p.m. - 2:45 p.m.	Workshops
-----------------------	------------------

1:15 p.m. - 2:45 p.m.

***Evolving Understandings of Psychedelics in Clinical Research**

Americana I

Chair: Francisco Moreno, University of Arizona

1:24 p.m. - 1:48 p.m.

Understanding Psilocybin Administration: Dose, Participant Characteristics, and Therapeutic Context

Namik Kirlic, Compass Pathways

1:48 p.m. - 2:12 p.m.

Recruiting, Retaining, and Tailoring Psychedelic Clinical Trials for Vulnerable Populations

Peter Hendricks, The University of Alabama At Birmingham

2:12 p.m. - 2:36 p.m.

Evaluating the Clinical Utility of Psilocybin Therapy versus Other Psychedelic Drug Interventions for the Treatment of Posttraumatic Stress Disorder

Brandon Weiss, Department of Psychiatry, Johns Hopkins University School of Medicine

Discussant: Matt Young, Compass Pathways, PLC



1:15 p.m. - 2:45 p.m.

***^Durability Outcomes in Treatment Resistant Depression**

Americana 2

Chair: Scott Aaronson, Sheppard Pratt

1:20 p.m. - 1:38 p.m.

Transcranial Magnetic Stimulation: Durability of Anti-Depressant Response

Saydra Wilson, The University of Minnesota

1:38 p.m. - 1:56 p.m.

Durability of Vagus Nerve Stimulation Treatment-Resistant Depression: New, More Comprehensive Findings From the Recover Trial

Charles Conway, Washington University in St. Louis

1:56 p.m. - 2:14 p.m.

Beyond the Acute Course: Exploring the Durability of Ketamine's Antidepressant Effects in the Maintenance Phase of Treatment

Joshua Rosenblat, University of Toronto

2:14 p.m. - 2:32 p.m.

How Durable Are Acute Effects of Psilocybin on Treatment-Resistant Depression?

Trisha Suppes, Stanford University

Discussant: A. Rush, Curbstone Consultant LLC

1:15 p.m. - 2:45 p.m.

Building Collaborative Capacity in Early Career Psychopharmacology: Strategies for Effective Partnerships Across Academia, Industry, and Clinical Practice

Poinciana 1 and 2

Chair: Keren Bachi, The Addiction Institute of Mount Sinai; Icahn School of Medicine at Mount Sinai

Co-Chair: Rana Jawish, University of Utah School of Medicine

1:20 p.m. - 1:32 p.m.

The Evolving Nature of Academic-Industry Partnerships

Mark Rapaport, American Psychiatric Association

1:32 p.m. - 1:44 p.m.

Take-Aways from My Experience Starting out in Clinical Psychopharmacology Research

Anita Clayton, University of Virginia SOM

1:44 p.m. - 1:56 p.m.

Why Do We Need Team Science Approaches in Neurobiological and Clinical Studies

Vilma Gabbay, Miller School of Medicine, University of Miami

1:56 p.m. - 2:08 p.m.

Development of Esketamine.. an Academic -Industry Dream Collaboration

Jaskaran Singh, Neurocrine Biosciences

2:08 p.m. - 2:20 p.m.

Are Early Career Clinical Researchers in Psychiatry an Endangered Species?



Dan Iosifescu, New York University School of Medicine

2:20 p.m. - 2:32 p.m.

The Young Investigator as a Pluripotent Stem Cell: The Role of Industry-Academic Partnerships in a Successful Career

Charles Nemeroff, The University of Texas At Austin

Discussant: Manish Jha, University of Texas Southwestern Medical Center

1:15 p.m. - 2:45 p.m.

^Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Poinciana 3 and 4

Chair: Ynhi Thomas, Baylor College of Medicine and Michael E. DeBakey VA Medical Center

Co-Chair: Erica Kaczmarek, University of Toronto

1:25 p.m. - 2:35 p.m.

Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Erica Kaczmarek, University of Toronto

1:25 p.m. - 2:35 p.m.

Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Nidhi Kulkarni, Centre for Youth Bipolar Disorder, CAMH

1:25 p.m. - 2:35 p.m.

Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Ivan Montoya, DHHS/National Institute on Drug Abuse

1:25 p.m. - 2:35 p.m.

Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Holly Swartz, University of Pittsburgh School of Medicine

1:25 p.m. - 2:35 p.m.

Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Crystal Clark, University of Toronto, Women's College Hospital

1:25 p.m. - 2:35 p.m.

Communication and Conflict Management: Practical Tools for Effective Leadership in Research

Nicholas Murphy, Texas A&M University, Naresh K. Vashisht College of Medicine

Discussant: Danica Johnson, University of Toronto

3:00 p.m. - 4:30 p.m.	Panel Sessions
-----------------------	-----------------------

3:00 p.m. - 4:30 p.m.



^Advances in Depression Research: A Tribute to Nolan Williams

Americana 1

Chair: Charles Nemeroff, The University of Texas At Austin

3:09 p.m. - 3:33 p.m.

Understanding and Harnessing the Opioid Effects of Ketamine

Alan Schatzberg, Stanford Univ. School of Medicine

3:33 p.m. - 3:57 p.m.

Non-Invasive Amygdala Neuromodulation in Humans with Focused Ultrasound:

Neurobiological and Clinical Effects in Mood, Anxiety, and Trauma-Related Disorders

Gregory Fonzo, The University of Texas at Austin Dell Medical School

3:57 p.m. - 4:21 p.m.

Clinical and Neural Outcomes of Magnesium-Ibogaine for Traumatic Brain Injury in Special Operations Forces Veterans

Ian Kratter, Stanford University School of Medicine

Discussant: Charles Nemeroff, The University of Texas At Austin

3:00 p.m. - 4:30 p.m.

***^Photobiomodulation With Near Infrared Light: A Novel Treatment for Psychiatric Disorders**

Americana 2

Chair: Dan Iosifescu, New York University School of Medicine

3:09 p.m. - 3:27 p.m.

Dose-Dependent Effects of Transcranial Photobiomodulation on Brain Temperature in Patients with Major Depressive Disorder: A Spectroscopy Study

Paolo Cassano, Massachusetts General Brigham

3:27 p.m. - 3:45 p.m.

Transcranial Photobiomodulation for Alzheimer's Disease

Dan Iosifescu, New York University School of Medicine

3:45 p.m. - 4:03 p.m.

Transcranial Infrared Laser Stimulation Improves Cognitive Performance and Induces a Biphasic Cerebral Perfusion Response in Remitted Bipolar Disorder

Jorge Almeida, The University of Texas At Austin

4:03 p.m. - 4:21 p.m.

Uncovering Mechanisms of Photobiomodulation behind Clinical Changes: Evidence from Neuroimaging

Naomi Gaggi, New York University Grossman School of Medicine

Discussant: Luis De Taboada, NeuroThera

3:00 p.m. - 4:30 p.m.

***^Developing Treatments for the Non-Motor Symptoms of Parkinson's Disease**

Poinciana 1 and 2

Chair: Gerard Sanacora, Yale University, New Haven, CT, USA

3:09 p.m. - 3:33 p.m.



AB-300, a Novel 5-HT_{2A/2C} Agonist, Reverses Motivational Deficits in a Tetrabenazine Model of Parkinson's Disease Apathy

Daniel Jeffries, Ariadne Bio

3:33 p.m. - 3:57 p.m.

Psilocybin Therapy for Depression in Parkinson's disease

Ellen Bradley, UCSF

3:57 p.m. - 4:21 p.m.

Targeting Synaptic Loss in Parkinson's Disease Depression With Ketamine

Sophie Holmes, Yale University

Discussant: Daniel Weintraub, University of Pennsylvania

3:00 p.m. - 4:30 p.m.

***Lessons From Transforming the Psychiatric Healthcare System: How to Improve Outcomes?**

Poinciana 3 and 4

Chair: Andrew Nierenberg, Massachusetts General Hospital

3:09 p.m. - 3:27 p.m.

Alignment for Progress: A Movement to Bring Change

Nathaniel Counts, The Kennedy Forum

3:27 p.m. - 3:45 p.m.

One Expert by Experience Journey

George McAllister, Bipolar Action Network

3:45 p.m. - 4:03 p.m.

Challenges of Building a Learning Health System for Early Psychosis Care

Lisa B Dixon, College of Physicians and Surgeons, Columbia University/New York State Psychiatric Institute

4:03 p.m. - 4:21 p.m.

Transforming the Healthcare System With the Bipolar Action Network

Andrew Nierenberg, Massachusetts General Hospital

Discussant: Crystal Clark, University of Toronto, Women's College Hospital

4:30 p.m. - 6:00 p.m.	Plenary Panel
-----------------------	---------------

Americana 3

4:30 p.m. - 6:00 p.m.

Artificial Intelligence: Understanding the Present and Anticipating the Future

Americana 3

Chair: Valentina Mantua, Center for Drug Evaluation and Research, Food and Drug Administration

Co-Chair: Roy Perlis, Massachusetts General Hospital

4:40 p.m. - 5:05 p.m.



Using Artificial Intelligence and Social Media Data for Population Mental Health Surveillance

Yulin Hswen, University of California - San Francisco

5:05 p.m. - 5:30 p.m.

Assessing AI for Clinical Care and Research

John Torous, Beth Israel Deaconess Med. Ctr. and Harvard Medical School

5:30 p.m. - 5:55 p.m.

Bridging AI Innovation and Clinical Trial Data in Psychiatry: Mathematical Limits and Clinical Consequences

Joseph Geraci, NetraMark Holdings



8:30 a.m. - 10:00 a.m.	Panel Sessions
------------------------	----------------

8:30 a.m. - 10:00 a.m.

***What to Know About Ketamine Safety: Patient Monitoring, Neurotoxicity, and Considerations for Special Patient Populations**

Americana 1

Chair: Benjamin Brody, Weill Cornell Medical College

8:39 a.m. - 9:03 a.m.

Racemic Ketamine Side effects, Adverse Reactions, and Monitoring

Benjamin Brody, Weill Cornell Medical College

9:03 a.m. - 9:27 a.m.

Ketamine for Depression, but at What Cost? Evidence for Neurotoxicity From Human and Animal Studies

Samuel Wilkinson, Yale School of Medicine

9:27 a.m. - 9:51 a.m.

Use of Ketamine for Depression in Special Populations

Joshua Rosenblat, University of Toronto

Discussant: Cristina Cusin, Massachusetts General Hospital

8:30 a.m. - 10:00 a.m.

***^The Discovery and Clinical Development of (2R,6R)-Hydroxynorketamine for Depression and Pain**

Americana 2

Chair: Todd Gould, University of Maryland School of Medicine

Co-Chair: Carlos Zarate, National Institute of Mental Health

8:39 a.m. - 8:57 a.m.

From Ketamine Metabolite to Candidate Therapeutic: Preclinical Discovery of (2R,6R)-HNK Relevance to Depression Treatment

Todd Gould, University of Maryland School of Medicine

8:57 a.m. - 9:15 a.m.

Preclinical Development of (2R,6R)-Hydroxynorketamine for Human Clinical Evaluation

Craig Thomas, NCATS, NIH

9:15 a.m. - 9:33 a.m.

Clinical Development of (2R,6R)-Hydroxynorketamine: Ongoing Trials in TRD and OCD and Phase 1 Safety, Tolerability, and PK/PD Results in Healthy Volunteers

Carlos Zarate, National Institute of Mental Health

9:33 a.m. - 9:51 a.m.

Evaluation of the (2R,6R)-Hydroxynorketamine as a Potential Clinical Useful Analgesic agent: Translational Experience from Preclinical to Human Study

Robert McCarthy, Rush University Medical Center

Discussant: Dawn Ionescu, Johnson and Johnson Pharmaceutical



8:30 a.m. - 10:00 a.m.

The Future DSM: Designing a Scientific, Inclusive, and Practical Diagnostic Manual for Modern Psychiatry

Poinciana 1 and 2

Chair: Nitin Gogtay, American Psychiatric Association

8:39 a.m. - 9:03 a.m.

The Future DSM: Designing a Scientific, Inclusive, and Practical Diagnostic Manual for Modern Psychiatry

Jonathan Alpert, Albert Einstein College of Medicine

9:03 a.m. - 9:27 a.m.

Structure and Dimensions Subcommittee

Dost Ongur, Harvard Medical School/McLean Hospital

9:27 a.m. - 9:51 a.m.

The DSM Subcommittee on Candidate Biomarkers and Biological Factors

Anissa Abi Dargham, State University of New York At Stony Brook

Discussant: Nitin Gogtay, American Psychiatric Association

8:30 a.m. - 10:00 a.m.

***^New and Anticipated Interventions for Perinatal Depression**

Poinciana 3 and 4

Chair: Anita Clayton, University of Virginia SOM

8:39 a.m. - 8:57 a.m.

Pathophysiological Mechanisms of Perinatal Depression

Kristina Deligiannidis, Zucker Hillside Hospital

8:57 a.m. - 9:15 a.m.

Epigenetic Biomarkers in Postpartum Depression and Postpartum Psychosis

Jennifer Payne, University of Virginia

9:15 a.m. - 9:33 a.m.

Approved and Potential Treatments for PPD

Anita Clayton, University of Virginia SOM

9:33 a.m. - 9:51 a.m.

Addiction and Neuromodulation in Pregnancy

Rana Jawish, University of Utah School of Medicine

Discussant: Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health, Boston, MA

10:30 a.m. - 11:30 a.m.	Regulatory Challenges
-------------------------	------------------------------

Americana 2

10:30 a.m. - 11:30 a.m.

Regulatory Challenges: Ask the Experts

Americana 2



Chair: Tiffany Farchione, US Food and Drug Administration

10:35 a.m. - 11:30 a.m.

Regulatory Challenges: Ask the Experts

Tiffany Farchione, US Food and Drug Administration

10:35 a.m. - 11:30 a.m.

Regulatory Challenges: Ask the Experts

Valentina Mantua, Center for Drug Evaluation and Research, Food and Drug Administration

10:35 a.m. - 11:30 a.m.

Regulatory Challenges: Ask the Experts

Bernard Fischer, U.S. Food and Drug Administration



Wednesday, May 27, 2026
11:45 a.m. - 1:30 p.m.

Poster Session I with Lunch
Americana Ballroom

W1. The Phase 2/3 Gain Trial of the First-Generation P. Gingivalis Gingipain Inhibitor Atuzaginstat in Mild-To-Moderate Probable Alzheimer's Disease: New Cerebrospinal Fluid Biomarker Data

Michael Detke*, Marwan Sabbagh, Joanna Bolger, Mark Ryder, Craig Mallinckrodt, Florian Ermini, Casey Lynch, Stephen Dominy
Michael Detke, Lighthouse Pharma

W2. Galantamine-Memantine Combination Regulating the Kynurenine Pathway Metabolism in the Treatment of Post-Stroke Depression and Post-Stroke Cognitive Impairments and Prevention of Stroke

Anne Khodarkovskaya*, Kwame Amonu, Bruno Pillari, Yaxel Levin-Carrion, Maju Koola
Anne Khodarkovskaya, Cooper Medical School of Rowan University

W3. Dynamic Causal Modeling of Triple-Network Connectivity Varies by Suicide Attempt History

Benjamin Chandler*, Carlos Cortes, Hiroe Hu, Brady Greene, Adam Fijtman, Carlos Zarate, Elizabeth Ballard, Jessica Gilbert
Benjamin Chandler, Division Intramural Research Program, National Institute of Mental Health

W4. A Review of Evidence and an Algorithm for Use of Psychopharmacology in the Treatment of Tobacco Use Disorder in Behavioral Health Settings

Afrah Mohammad*, David Osser
Afrah Mohammad, VA Boston Healthcare System/Harvard Medical School

W5. Evidence From Randomized Controlled Trials in Substance Use Disorders With Memantine, Galantamine, N-Acetylcysteine, and Doxazosin/Prazosin

Kristine Hawkins*, Elizabeth G. Varghese, Sajoy P. Varghese, MD, Maju Mathew Koola, MD
Kristine Hawkins, Cooper Medical School of Rowan University

W6. Changes in Smoking-Related Outcomes With Tirzepatide in Individuals With Methamphetamine Use Disorder Who Smoke

Nandini Jha*, Amrita Ghose, Manish Jha, Abu Minhajuddin, Christian Hendershot
Nandini Jha, UTSW Medical Center Dallas

W7. Changes in Depressive Symptoms With Tirzepatide in Individuals With Moderate-To-Severe Methamphetamine Use Disorder

Virgilio Garza*, Amrita Ghose, Teresa Slettebo, Nandini Jha, Elizabeth Dedrick, Snoben Kuruvila, Manish Jha
Virgilio Garza, The University of Texas Southwestern Medical Center

W8. Safety and Tolerability of 32-Week-Long Treatment With Tirzepatide in Individuals With Moderate-to-Severe Methamphetamine Use Disorder



Amrita Ghose*, Virgilio Garza, Teresa Slettebo, Nandini Jha, Elizabeth Dedrick, Snoben Kuruvila, Manish Jha
Amrita Ghose, The University of Texas Southwestern Medical Center

W9. First Dose Treatment Effects With Injectable Weekly and Monthly Buprenorphine (CAM2038) and the Relationship Between Buprenorphine Plasma Concentrations and Withdrawal Suppression in Participants With Opioid Use Disorder

Michael P. Frost, Edward V. Nunes, Michelle R. Lofwall, Sharon L. Walsh, Genie L. Bailey, Brian J. Dawson, Natalie R. Budilovsky-Kelley*, Adam Friedman, Carrie Kaempfer, Joshua M. Cohen
Natalie R. Budilovsky-Kelley, Braeburn Inc, Plymouth Meeting

W10. A New Dawn for Social Anxiety Treatment: Clinical Advancement of the Novel V1aR Antagonist, NTX-1472

Tiffany Lago*, Marcelo Gutierrez, Solen Pichereau, Adam Simmons, Sonda Smyrniotis, Federico Bolognani
Tiffany Lago, Newleos Therapeutics

W11. Treatment Patterns Among Incident and Persistent Patients With Generalized Anxiety Disorder (GAD)

Erin Ferries*, Derek Louie, Susan Suponcic, Kaushik Rai, Katherine Park, Mark Gallivan, Felix Lam, Abigail Silber, Matthew O'Hara, Phong Duong, Jeffrey Strawn, Roger McIntyre
Erin Ferries, Definium Therapeutics

W12. The Impact of Comorbid Psychiatric Disorders on Misconducts Among Incarcerated Individuals With Attention-Deficit/Hyperactivity Disorder: A Preliminary Study

Elssa Toumeh*, Gunter Lorberg, David Runnalls, Alexandria Greifenberger, Kathryn Fotinos, Tia Sternat, Irvin Epstein, Martin Katzman
Elssa Toumeh, START Clinic for Mood and Anxiety Disorders

W13. The Neurochemical and Anxiolytic-Like Effects of Centanafadine in Preclinical Assays in the Rat and Mouse

Reem Elbekai, Michele Hummel, Gregory Parks*, David J. Heal, Takayuki Senriuchi, Tetsuro Kikuchi
Gregory Parks, Otsuka Pharmaceutical Development and Commercialization, Inc.

W14. Growing Trend of Stimulant Use in Young Patients Misdiagnosed With ADHD: A Case-Based Systematic Review

James Chua*, Mujeeb Shad
James Chua, College of Osteopathic Medicine, Touro University

W15. Emotional Dysregulation Symptom Outcomes in Adults With ADHD Treated With Centanafadine: A Pooled Post hoc Analysis of Two Phase 3 Trials

Jeffrey Newcorn, Joel Young, Caroline L. Ward, Dorothee Oberdan, Zhen Zhang, Paul Geiger, Lenard A. Adler*
Lenard A. Adler, NYU School of Medicine

W16. The Persistence of Neuroepithelial Progenitors in Neocortical Organoids: Impeding Accurate Models for Drug Screening in Neurodevelopmental Disorders



Konstantina Psychogyiou, Periklis Malakates, John F. Fullard, Faith De Kuyper, Panos Roussos, Deepak Kaji*
Deepak Kaji, Icahn School of Medicine at Mount Sinai

W17. Long-Term Safety and Tolerability of Cariprazine in Pediatric Patients With Autism Spectrum Disorder, Bipolar I Disorder or Schizophrenia: Final Results From an Open-Label Study

Marshall B. Lucas, Diab Almhana, Jeffery R. Strawn, Robert Riesenber, Elaine Smith*, Amin Shirazi, Lauren Aronin, Shane Varughese, Marc S. Weinberg
Elaine Smith, AbbVie

W18. E2086, a Selective Orexin Receptor-2 Agonist: Study for Promoting Wakefulness in Patients With Narcolepsy Type 1

Bruce Corser, Jocelyn Cheng, Nancy Hall, Sumit Rawal, Margaret Moline*
Margaret Moline, Eisai Inc.

W19. The Complex Multi-System Symptom Inventory (CoMSS): A New Instrument to Assess Symptom Frequency, Impact, and Postural Dependence Across Multiple Central and Peripheral Autonomic Symptom Domains

Christine Cheah, Aaron Rosser, John Oakley, Rebecca Hendrickson*
Rebecca Hendrickson, VA Puget Sound Health Care System

W20. Static and Dynamic Disruptions of Salience-Network Flexibility in Veterans With Comorbid Mild TBI and Alcohol Use Disorder

Niki Sabetfakhri*, Sherry Livengood, Olusola Ajilore, Todd Parish, Amy Herrold
Niki Sabetfakhri, University of Illinois at Chicago College of Medicine

W21. Successful Early Treatment of Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated With Small Cell Lung Cancer in an Elderly Male Patient: A Case Report

Yuya Honda*, Kohei Kamikawa, Ryohei Takada, Harue Goto, Masato Honda, Yuki Nishi, Hiroaki Fukui, Takashi Okada
Yuya Honda, Nara Prefectural General Medical Center

W22. GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial

Michael E. Thase*, Brian Brennan, Rachael MacIsaac, Luca Pani, Velichka Valcheva, Wieslaw J. Cubala
Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenzo VAMC

W23. Examining the Impact of Patient-Centered Approaches on the Assessment and Management of Cognitive Impairment in Major Depressive Disorder

Michael E. Thase*, Rakesh Jain, Jeff Carter, Jacqueline Maytorena, Laura Simone, Larissa Jarzyl
Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenzo VAMC

W24. Seltorexant Versus Quetiapine Extended Release as Adjunctive Treatment in Major Depressive Disorder With Insomnia Symptoms: Phase 3 Trial



Yanina Flossbach, Sofie Mesens, Gahan Pandina*, Ryan Kelly, Yun Zhang, Haiyan Xu, Lu Xia, Wayne C. Drevets
Gahan Pandina, Johnson and Johnson

W25. Benefits of Adjunctive Vagus Nerve Stimulation in Difficult-To-Treat Depression: Outcomes of a Naturalistic European Cohort (RESTORE-LIFE) Compared to the Usa Recover Randomized Controlled Trial

R. Hamish McAllister-Williams, Tiago da Silva Costa, Bernhard T. Baune, James Blackwell, Maxine Dibué, Christoph Kraus, Ying Chieh (Lisa) Lee, Fritz-Georg Lehnhardt, Shannon Majewski, Christine Reif-Leonhard, Norbert Scherbaum, Maria Strauß, Allan Young, Koen Demyttenaere, Koen Demyttenaere*
Koen Demyttenaere, University Psychiatric Center KU Leuven

W26. Pooled Individual Patient Data Analysis of Three Phase 2 Trials Supports Vasopressin V1b Receptor Antagonism (BH-200 250 mg BID) as an Antidepressant Mechanism for the Treatment of Major Depressive Disorder (MDD)

Lars Arvastson, Daniel Gehrlach, Evangelos Papanastasiou, Meline Gevorgyan, Christine zu Eulenburg, Hans Eriksson*
Hans Eriksson, HMNC Brain Health

W27. Genetically Defined Subgroup Analysis Reveals Differential Response to Vasopressin V1b Antagonism in Patients With MDD Pre-Exposed to Antidepressant in the Current Episode: Post-Hoc Analysis of the Phase 2 Olive Trial

Caren Strote, Lars Arvastson, Christine zu Eulenburg, Daniel Gehrlach, Evangelos Papanastasiou, Bertram Müller-Myhsok, Hans Eriksson*
Hans Eriksson, HMNC Brain Health

W28. Characteristics of Depression Episodes to Inform Real-World Health States for Major Depressive Disorder and Treatment-Resistant Depression

Vicki Wing*, Yechu Hua, Joshua Liberman, Jonathan Darer, Lucinda Orsini, Shane O'Connor, Michael Ostacher
Vicki Wing, Compass Pathways

W29. Longitudinal Profiling of Treatment Trajectories in SSRI-Anchored MDD Using Agentic AI

Naveen Deevi, Eleni Venetsanakos, Adam Kramer, Manaswini Sugatoor, Erwin Estigarribia, Felice Shieh*, Samuel Herschkowitz
Felice Shieh, Headlamp Health

W30. Dimensions of Psychedelic Experience Predicting Antidepressant Response to Psilocybin Across Diagnoses

Andrew van der Vaart*, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold Sackeim, Scott Aaronson
Andrew van der Vaart, Sheppard Pratt Health System and University of Maryland School of Medicine

W31. Anxious Depression as Predictor of Clinical Outcomes in Treatment-Resistant Depression (ASCERTAIN-TRD)

Stefania Chaikali*, Clotilde Guidetti, Silvia Ioannou, Madhukar H. Trivedi, Richard Shelton, Dan V. Iosifescu, Michael E. Thase, Manish Jha, Sanjay J. Mathew, Charles Debatista,



Mehmet E. Dokucu, Olga Brawman-Mintzer, Glenn W. Currier, William Vaughn McCall, Mandana Modirrousta
Stefania Chaikali, Harvard Medical School/Massachusetts General Hospital

W32. Neuroactive Steroid Changes Pre- and Post-Ketamine During a Double-Blind, Crossover Clinical Trial: An Exploratory Study

Hiroe Hu*, Yoojin Lee, Peixiong Yuan, Mani Yavi, Lawrence Park, Mark Kvarta, Carlos Zarate
Hiroe Hu, National Institute of Mental Health

W33. Association of Major Depressive Disorder With Insomnia Symptoms With Healthcare Resource Use and Cardiovascular and Metabolic Conditions – Analysis of National Health and Nutrition Examination Survey

Hrishikesh Kale*, Zhiwen Liu, Alicia K. Campbell, Karen Johnston, Guo Li, Carmela Benson, Zhiheng Zhang
Hrishikesh Kale, Johnson and Johnson

W34. Esmethadone (REL-1017) in Patients With Antidepressant Tachyphylaxis: A Post Hoc Efficacy Analysis in a Pre-Randomization-Defined Subgroup

Clotilde Guidetti*, Anna Chiara Frigo, George I. Papakostas, Luca Pani, Sara De Martin, Giulia Serra, Massimo Apicella, Stefano Comai, Andrea Mattarei, Franco Folli, Marco Gentilucci, Marco Pappagallo, Paolo L. Manfredi, Maurizio Fava
Clotilde Guidetti, Massachusetts General Hospital, and Harvard Medical School

W35. Preclinical Behavioral and Pharmacological Characteristics of TN-001, a Novel, Non-Hallucinogenic Neuroplastogen for the Treatment of Major Depressive Disorder

Samuel Slocum, Elizabeth Cogan, Mark Demitrack*
Mark Demitrack, Transneural Therapeutics

W36. Metabolic Profile of Adjunctive Lumateperone 42 Mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Samar Madi, Michael Smith*, Craig Chepke
Michael Smith, Intra-Cellular Therapies, a Johnson and Johnson Company

W37. Lumateperone 42 Mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial

Raffaele Migliore, Willie R. Earley, Suresh Durgam, Yifan Mo, Joanna Armas-Datorre*, Susan G. Kornstein
Joanna Armas-Datorre, Intra-Cellular Therapies, a Johnson and Johnson Company

W38. Efficacy of Lumateperone 42 Mg for the Treatment of Major Depressive Disorder: Analysis of Demographic and Clinical Subgroups in a Phase 3 Randomized Placebo-Controlled Trial

Suresh Durgam, Willie R. Earley, Dennis Sholler*, Hassan Lakkis, Roger S. McIntyre, Maurizio Fava
Dennis Sholler, Intra-Cellular Therapies, a Johnson and Johnson Company

W39. Psychopharmacology of ENX-104: A Potent Dopamine (DA) D2/D3 Receptor Antagonist for the Treatment of Neuropsychiatric Disorders Associated With Anhedonia



Robin Geever*, Alexander Coppel, Krishna Vadodaria, Laura Borghans, Titiaan Post, Karlo Nežić, Joseph Horrigan, Sean Kipperman, Stephanie Parks, Natalia Serrano, Vikram Sudarsan, Eve Taylor, Kimberley E. Vanover, Gabriel Jacobs, Estibaliz Arce
Robin Geever, Centre for Human Drug Research, Leiden, The Netherlands

W40. Impact of GH001 on Depressive Symptoms, Anxiety, and Quality of Life in Treatment-Resistant Depression: Results From a Phase 2b Trial

Wiesław J. Cubała*, Brian Brennan, Tiffanie Benway, David Gregory, Rachael MacIsaac, Michael E. Thase
Wiesław J. Cubała, Medical University of Gdańsk, Gdańsk, Poland

W41. Rapid and Sustained Improvement in Anhedonia Following Inhaled Mebufotenin (GH001) Treatment in Patients With Treatment-Resistant Depression

Roger McIntyre*, Nathan P. Burns, Wiesław J. Cubała, Kelly Doolin, Lisa Harding, Velichka Valcheva, Michael E. Thase
Roger McIntyre, University of Toronto

W42. Effects of Dextromethorphan-Bupropion (45mg/105mg) in Participants With Major Depressive Disorder and Anxious Distress

Jeffrey Strawn, Graham M.L. Eglit, Shawn Alter*, Courtney Zeni, Caroline Streicher, Roger McIntyre
Shawn Alter, Axsome Therapeutics

W43. HJ-006: A Non-Hallucinogenic Synaptogenic Compound With Rapid and Sustained Antidepressant Efficacy

Li Zeng*, Yao Liu, Ya Geng, Yue zhu
Li Zeng, Jing Medicine Technology (Shanghai) Ltd.

W44. Patient Reported Outcome Response Following Treatment With Liafensine in ANK3 Biomarker Positive Patients With Treatment Resistant Depression

Larry Alphs*
Larry Alphs, Denovo Biopharma LLC

W45. Psychomotor Disturbance as a Predictor of Treatment Response in Mood Disorders: A Systematic Review

Sara Di Luch*, Gabrielle Lovell, Lily Jiang, Diana Orsini, Shreya Vasudeva, Gia Han Le, Sabrina Wong, Rachel Ospalak, Rodrigo Mansur, Alastair Flint, Joshua Rosenblat
Sara Di Luch, University of Toronto

W46. The Monotherapy Antidepressant Pipeline Problem: Only 8 Approvals out of 28 Attempts in the Last 25 Years

Anshu Arora*, Mahima Patil, Aishwarya Prasad, Lydia Perry, Kyle Stupfel, Arif Khan
Anshu Arora, Northwest Clinical Research Center

W47. Early Response to Psilocybin in Adults With Treatment-Resistant Depression as a Predictor for Antidepressant Efficacy

Noah Chisamore*, Zoe Doyle, Erica Kaczmarek, Danica Johnson, Roger McIntyre, Joshua Rosenblat
Noah Chisamore, University of Toronto

**W48. Early Motivational and Hedonic Responses to Antidepressants in Major Depressive Disorder: A Real-World Evidence Study**

Maurice M. Ohayon, Stéphanie Duhoux, Maggie McCue, Michael Martin, Priscilla Driscoll Shempp*, Andrew Krystal, Marie-Lise Côté
Priscilla Driscoll Shempp, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA

W49. Real-World Evidence of the Clinical and Preference Impact of a Prescription Digital Therapeutic for Major Depressive Disorder: An Ongoing Prospective Study in an Academic Health System

Sarah Small*, Joseph Raiker, Carl Asche, Connor Willis, Haopeng Liu, Joanita Lake, Amber Mackey, Tomas Melicher, Anthony May
Sarah Small, Otsuka

W50. Anxiolytic Effects of Dextromethorphan-Bupropion (45mg/105mg): Post Hoc Analyses Across Trials in Major Depressive Disorder

Jeffrey Strawn, Shawn Alter, Courtney Zeni*, Caroline Streicher, Graham M.L. Eglit
Courtney Zeni, Axsome Therapeutics

W51. Multimodal Identification of Neurobiological Subtypes Associated With Ketamine Response in Treatment-Resistant Depression Using NetraAI

Joseph Geraci, Bessi Qorri, Jan Sedway*, Christian Cumbaa, Mike Tsay, Paul Leonchyk, Larry Alphs, Elizabeth Ballard, Carlos Zarate, Jr., Luca Pani
Jan Sedway, NetraMark

W52. Orexin 2 Receptor Agonists as a Potential Therapeutic Approach to the Treatment of Sleep-Wake Disturbance, Fatigue, and Cognitive Deficit in Neuropsychiatric Disease

David Plante*, Andrew J. Cutler, Ishani Landry, Bhaskar Rege, Julie Himes, Craig Hopkinson, Emmanuel Mignot
David Plante, University of Wisconsin School of Medicine and Public Health

W53. A Novel Disease-Modifying Strategy for Narcolepsy Type 1 – Preclinical Rationale and Development Roadmap for the Doxa Platform

Eric Konofal*, Kfir Molakandov, Michel Revel, Anh-Tuan Lormier, Maxime Robin, Christelle Peyron, Jean-Charles Bizot
Eric Konofal, University of Paris, Robert-Debré Hospital, France

W54. Targeted Eligibility Review Can Decrease the Number of Inappropriate Participants Enrolled in Clinical Trials

Chris Mikesell*, Sabine Krofczik-Wilhelm, Anna Gonzaga
Chris Mikesell, PPD Development

W55. IMPACT-EXT: Evaluating the Durability and Redosing of TSND-201 (Methylone) for the Treatment of PTSD

Jennifer Warner-Schmidt*, Amanda Jones, Hannah Kwak, Ashley Lauritsch, Carolyn Macleod, Martin Stogniew, Blake Mandell, Benjamin Kelmendi
Jennifer Warner-Schmidt, Transcend Therapeutics

W56. Safety, Pharmacokinetics, and Pharmacodynamics of MSD-001 After Single Dosing in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Study



Fas Krol*, Gabriel Jacobs, Thomas Ray, Andrew Thieme, Laura Borghans, Kenneth Colley, Tilmann Brotz, Dillan DiNardo, Robert Silva, Josie Kins
Fas Krol, Centre for Human Drug Research, Leiden, The Netherlands; Leiden University Medical Center, The Netherlands

W57. Blinding Integrity in Psychedelic Randomized Controlled Trials: A Systematic Review

Diana Orsini*, Sabrina Wong, Sara Di Luch, Brendan Chan, Shreya Vasudeva, Gabrielle Lovell, Gia Han Le, Brett Jones, Noah Chisamore, Adriano Mollica, Danica Johnson, Ishrat Husain, Matthew Burke, Roger McIntyre, Joshua Rosenblat
Diana Orsini, University of Toronto

W58. Unlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-Targeting Prodrug Technology

Antony Loebel, Sergey Yagoda*, Daniel K. Bonner, Jamie S. Simpson, Michael C. Chen
Sergey Yagoda, Seaport Therapeutics

W59. A Randomized, Placebo-Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Rodrigo Machado-Vieira*, Alan C. Courtes, Ana C. Ruiz, Abdul Hasseb, Lokesh Shahani, Jair Soares, Scott D. Lane
Rodrigo Machado-Vieira, McGovern Medical School, University of Texas Science Center in Houston

W60. Efficacy, Safety and Tolerability of Lysergic Acid Diethylamide for the Treatment of Depressive Symptoms: A Meta-Analysis and Systematic Review

Andreea Chiorean*, Helena Kim, Andrew Lustig, Ishrat Husain
Andreea Chiorean, University of Toronto

W61. Beyond Mood: Broader Psychological Benefits of IV Ketamine for Major Depressive Disorder

Lauren Eide*, Simon Kung, Jennifer Vande Voort, Balwinder Singh
Lauren Eide, Mayo Clinic

W62. The Complex Diagnostic Profile of Psychiatric Outpatients Presenting for the Treatment of Bipolar Depression

Mark Zimmerman*, Barbara Lu
Mark Zimmerman, Brown University

W63. Sodium-Glucose Cotransporter-2 Inhibitors Reduce Suicidality, All-Cause Mortality, and Hospitalization in Bipolar Disorder: A Cohort Study of 1.23 Million Adults

Balwinder Singh*, Raman Baweja
Balwinder Singh, Mayo Clinic

W64. Preclinical Efficacy of Concomitant Administration of Novel GSK3 β Inhibitor 4MT-A and Lithium Orotate

Sarina Mohanty, Amanda Roberts, Aaron Motacek, Haggarty Stephen, Pablo Lapuerta*
Pablo Lapuerta, 4M Therapeutics



W65. The Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: Protocol and Interim Analysis of Clinical Outcomes

Erica Kaczmarek*, Nelson Rodrigues, Zoe Doyle, Noah Chisamore, Danica Johnson, Maya Stern, Joshua D Rosenblat

Erica Kaczmarek, University of Toronto

W66. Effect of Cariprazine Treatment on Sleep and Mood Symptoms in Patients With Bipolar I Depression and Baseline Sleep Disturbance: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials

Manpreet Kaur Singh, Jeffery R. Strawn, James Fratantonio, Resmi Gupta, Lauren Aronin*, Andrew J. Cutler

Lauren Aronin, AbbVie

W67. An Open-Label, Two-Arm Study of Ketamine's Effects on Fluid Cognition in Mood Disorders With and Without Psychosis

Adam Fijtman*, Poulomi Mitra, Elizabeth Ballard, Kelly Hurst, Rachel Rans, Jessica Gilbert, Katherine Burdick, Carlos Zarate

Adam Fijtman, NIH/NIMH

W68. Tirzepatide Precipitating Acute Lithium Toxicity in Stable Bipolar I Disorder

Edith Liliana Patarroyo Rodriguez*, Jonathan Leung, Balwinder Singh

Edith Liliana Patarroyo Rodriguez, Mayo Clinic

W69. Effects of Cariprazine on Symptoms of Anxiety: A Pooled Post Hoc Analysis of Double-Blind Clinical Trials in Patients With Depression

Maurizio Fava, Rakesh Jain, Lauren Aronin, Resmi Gupta, Maija Krumins, Simranpreet Waraich*

Simranpreet Waraich, AbbVie

W70. Real-World Impact on Anxiety Symptoms of Cariprazine as Adjunctive Treatment in Major Depressive Disorder or Monotherapy in Bipolar I Disorder

Roger S. McIntyre, Rahul Khairnar*, Nadia Nabulsi, Simranpreet Waraich, Emily O.C. Palmer, Rose Sisk, Laila Hadaya, Nadia Lipunova, Subina Surendran, Mousam Parikh

Rahul Khairnar, AbbVie

W71. Antipsychotic Switching Among Patients With Bipolar I Depression After Initiating Cariprazine Vs Lumateperone: A Real-World Claims-Based Study

Andrew J. Cutler, Rahul Khairnar*, Nadia Nabulsi, Mousam Parikh, Enrico Zanardo, Sophie Ma, Susannah Ripley, François Laliberté, Jeffery R. Strawn

Rahul Khairnar, AbbVie

W72. Comparative Efficacy of Bupropion Vs Selective Serotonin Reuptake Inhibitors in Antidepressant-Naïve, Obese Patients With Major Depressive Disorder

Farah Khorassani*, Justin Schneider, Jonathan Pruneau, Gemma Espejo

Farah Khorassani, University of California, Irvine School of Pharmacy and Pharmaceutical Sciences

W73. Effect of Psychedelic Therapies on Sleep in Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Gregory Dance*, Stanley Wong, Terri Rodak, Tushar Sood, Nour Kanaa, Samuel Fischer, Joshua D. Rosenblat, Daphne Voineskos, M. Ishrat Husain



Gregory Dance, University of Toronto

W74. Impact of Seltorexant on Cognitive Performance of Adults With Major Depressive Disorder With Insomnia Symptoms

Amy Wegener*, Ryan Kelly, Yun Zhang, Randall L. Morrison, Yanina Flossbach, Sofie Mesens, Wayne C Drevets, Gahan Pandina
Amy Wegener, Johnson and Johnson, Titusville, NJ; Drexel University College of Medicine

W75. Intermittent White Light at 60 Hz as a Potential Neurostimulation Approach for Depression: Effects on EEG Activity and Safety in Healthy Human Volunteers

Maria Teresa Ferretti*, MohammadAmin Alamalhoda, Friederike Leesch, Francesca Giovanetti, Eoghan Dunne, Giuseppina Pilloni, Mark Caffrey, Jack O'Keeffe, Leigh Charvet, Andre Brunoni, Kallene Vidal, Primavera Spagnolo, Alessandro Venturino
Maria Teresa Ferretti, Syntropic Medical, Austria

W76. Safety and Efficacy of Full and Half-Dose Neuronavigated Accelerated Theta Burst Tms in Treatment-Naïve Adolescent Depression

Sean O'Sullivan*, Elyse Lemke, Emma Ableman, Juneid Mosaheb, Austin Herrman, J. Michele LaGrone, Charles Nemeroff, Nolan Williams
Sean O'Sullivan, The University of Texas at Austin

W77. Real-World Evidence From Legal Psilocybin-Assisted Services in Oregon: Psychedelic Preparedness and Experiential Predictors of Mental Health Outcomes

Robert Dougherty*, Emily Shih, Amanda Gow, Ryan Reid, Jimmy Qian, Robin Carhart-Harris, Jennie Davis
Robert Dougherty, Osmind

W78. Protocol for Real World Safety and Effectiveness Study of Psilocybin Therapy

Alexandra Gordon*, Hope Kronman, Brennan Carrithers, Noam Goldway, Silver Liftin, Stephen Ross, Broc Pagni, Richard Zeifman
Alexandra Gordon, NYU Langone Center for Psychedelic Medicine

W79. Real-World Experience and Impact of Fatigue in Narcolepsy and Idiopathic Hypersomnia From the ASPIRE Survey Study

Michael Doane*, Gretchen Murphy, Jane Lazar Tucker, Kristen McCausland, Claire Wylds-Wright, Lindsay Jesteadt
Michael Doane, Alkermes, Inc.

W80. Activation of σ 1R and 5-HT_{2A} Pathways Modulates Neuroinflammation, Glial Repair Programs, and BBB Responses in Demyelinating CNS Models

Ying Yu, Wieslaw J. Cubala, Aleksandra Rutkowska*
Aleksandra Rutkowska, Medical University of Gdańsk, Poland

W81. Examining the Impact of Trauma on Ketamine's Efficacy in Bipolar I/II Depression: A Secondary Analysis From a Randomized, Midazolam-Controlled Trial

Danica Johnson*, Diana Orsini, Sara Di Luch, Gabrielle Lovell, Shreya Vasudeva, Nelson Rodrigues, Rodrigo Mansur, Roger McIntyre, Joshua Rosenblat
Danica Johnson, University of Toronto

W82. Real-World Persistence on Olanzapine/Samidorphan Versus Other Oral Second-Generation Antipsychotics in Patients With Schizophrenia



Andrew J. Cutler, MD*, Christoph U. Correll, MD, Rakesh Jain, MD, MPH, Craig Chepke, MD, Hara E. Oyedeji, DNP, PMHNP-BC, Alejandro G. Hughes, MPH, Noah S. Webb, PhD, Michael J. Doane, PhD, Hemangi R. Panchmatia, MSc
Andrew J. Cutler, MD, SUNY Upstate Medical University, Syracuse, NY, USA;
Neuroscience Education Institute

W83. Using Artificial Intelligence/Machine Learning and Real-World Data to Identify Patients With Schizophrenia for Whom an Aripiprazole Monohydrate LAI is Likely to Be a Favorable Treatment Option

Christoph U Correll, Jason Jones, Bharath Ravichandran*, Karimah S. Bell Lynum, Norman Atkins, Jr., Soma S. Nag, Kristine Harrsen, Anne M. Hutson Walker, Tiffany Yu, Bartek Augustyniak, Isaac Kirk-Koffi, Jr., Vincent Marino, Rachel Linker, Mauricio Tohen
Bharath Ravichandran, Guidehouse Consulting

W84. Endocrine Biomarkers of Suicide Risk in Schizophrenia

Sara Katherine Mourani*, Henry Nasrallah
Sara Katherine Mourani, Yale

W85. Clozapine's Antagonism is Robust Against Known DRD2 Mutations

Ranran French*, Akshi Pant, Ryan Gumpfer
Ranran French, UNC at Chapel Hill

W86. Impact of Negative Symptoms on Healthcare Resource Utilization and Costs in Schizophrenia: A Real-World Data Analysis

Nadia Lipunova, Joannas Yeow, Laila Hadaya, Emily O.C. Palmer, Subina Surendran, Kristin Gillard, Christoph U. Correll, Kristin Gillard*
Kristin Gillard, Bristol Myers Squibb

W87. Onset, Duration, and Incidence of Adverse Events by Dose and Titration Schedule of Xanomeline and Trospium Chloride

Rachel Dyme*, Jenna Hoogerheyde, Ayesha Pavithran, Ranjan Tiwari, James Appio, Andrew Thorpe, Scott Vuocolo, Ken Kramer
Rachel Dyme, Bristol Myers Squibb

W88. SUVN-L1101142, a Muscarinic M4 Positive Allosteric Modulator (M4 PAM) for the Treatment of Psychosis-Related Disorders and Condition

Venkatesh Goura, Mayur Kumbhare, Rajesh Babu Medapati, Kumar Bojja, Aamer Shaikh, Rajesh kumar Badange, Ankit Das, Naga Sai Soma Chandra Sekhar Guduru, Keerthi Sai Bitra, Mary Praveena Nissankarao, Hima Bindhu Bobbili, Anindita Jana, Sunitaben Gayakvad, Sushant Thoke, Ramakrishna Nirogi*
Ramakrishna Nirogi, Suven Life Sciences

W89. Occurrence of Urinary Retention-Related Adverse Events With Xanomeline and Trospium Chloride: Results From the 52-Week, Open-Label EMERGENT-5 Trial

Scott Vuocolo*, Rajiv Radhakrishnan, Pierre Nicolas, Monica Elias, Andrew Thorpe
Scott Vuocolo, Bristol Myers Squibb

W90. Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data

Leslie Citrome, MD, MPH, Christoph U. Correll, MD, Roger S. McIntyre, MD, Mark S. Todtenkopf, PhD, Christina Arevalo, MS, James A. McGrory, PhD*, David McDonnell, MD



James A. McGrory, PhD, Alkermes, Inc.

W91. Longitudinal Trends in Antipsychotic Polytherapy and Associated Outcomes in Schizophrenia

Rashmi Patel, Yichen Zhong, Weihua Gao, Doyoung Kim, James Appio, Brittany Albright, Weihua Gao*

Weihua Gao, Bristol Myers Squibb

W92. Efficacy and Safety of Xanomeline and Trospium Chloride for Mania in Bipolar Disorder: Design of the BALSAM-1 and BALSAM-2 Trials

Roger McIntyre, Steven Galati, Heshani DeSilva, Alessandro Previtali, Lauren Moran, Lauren Moran*

Lauren Moran, Bristol Myers Squibb

W93. Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder

Andrew J. Cutler, MD, Hemangi R. Panchmatia, MSc*, Alejandro G. Hughes, MPH, Michael J. Doane, PhD, Hara E. Oyedeki, DNP, PMHNP-BC, Rakesh Jain, MD

Hemangi R. Panchmatia, MSc, Alkermes, Inc.

W94. Translational Evidence for Dopaminergic Alteration of Basal Ganglia Functional Connectivity in Persons With Schizophrenia

John Williams*, Philip Tubiolo, Roberto Gil, Clifford Cassidy, Nataalka Haubold, Yash Patel, Sameera Abeykoon, Eilon Silver-Frankel, Greg Perlman, Jodi Weinstein, Christoph Kellendonk, Guillermo Horga, Mark Slifstein, Anissa Abi-Dargham, Jared Van Snellenberg
John Williams, Stony Brook University School of Medicine

W95. Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-Analysis of Randomized Controlled Trials

Sajoy Varghese*, Houlin Hong, Jack Donlon, Martin Schaefer, Susanne Sarkar, Dragana Bugarski-Kirola, Mujeeb Shad, Wei Hou, Matthias Kirschner, Ludmil Mitrev, Valentina Echeverria, John Dibato, Selene Veerman, Trevor Stone, Maju koola

Sajoy Varghese, Clinical Resource Hub, VISN 23, Minneapolis VA Health System

W96. Deliberate Self-Harm in Bosnia and Herzegovina (BiH), With Special Reference to Gender, Age and Ethnicity

Emina Music*

Emina Music, Psychiatric clinic, Norra Alvsborgs Länssjukhus, Trollhattan, Sweden

W97. Risk of Suicide Attempt in Newly Diagnosed ADHD With and Without Stimulant Treatment Within Three Months of Diagnosis

Benjamin George*, David Kaelber, Malcolm Vaught

Benjamin George, Cape Fear Valley Hospital

W98. Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of Lpcn 1154A

Anthony DelConte*, Joshua C Weavil, Jonathan Ogle, Min-Jee Goh, Benjamin J Bruno, Nachiappan Chidambaram, Mahesh V Patel, Kristina M. Deligiannidis

Anthony DelConte, Lipocine

**W99. Acute Treatment of Postpartum Psychosis: An Update From the Massachusetts General Hospital Postpartum Psychosis Project**

Lee Cohen*, Peri Barest, Lily Cork, Samantha Pegg, Hannah Yoon, Rachel Vanderkruik, Marlene Freeman

Lee Cohen, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

W100. RE104: A Novel Serotonergic Psychedelic 4-OH-DiPT Prodrug for the Treatment of Postpartum Depression

Mark Pollack*, Anita Clayton, Camille Hoffman, Peter Hendricks, Daniel Fallon, Lawrence Leeman, Matthew Johnson, Beatrix Taylor, Jasna Hocevar-Trnka, Nathan Bryson, Joe Hirman, Robert Alexander, Stephen Ross

Mark Pollack, Reunion Neuroscience

W101. Use of Long-Acting Injectable Antipsychotics in Forensic Psychiatry: A Multi-Site Canadian Study

Andrew Olagunju*, Mark Kaggwa, Joan Abaatyo, Gary Chaimowitz

Andrew Olagunju, McMaster University

W102. Suicide Risk of Third-Generation Antipsychotics in Persons With Schizophrenia and Schizoaffective Disorders: A Systematic Review and Meta-Analysis

Jeff Jin*, Charlotte Winkler, Heather Blunt, Natalie Riblet

Jeff Jin, Dartmouth-Hitchcock Medical Center

W103. Aripiprazole Once-Monthly for Patients Living With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Leslie Citrome, Karimah S. Bell Lynam, Zhen Zhang, Anne M. Hutson Walker, Norman Atkins, Jr., Murat Yildirim, Leslie Citrome*

Leslie Citrome, New York Medical College

W104. Medetomidine- An Emerging Adulterant

Thersilla Oberbarnscheidt*

Thersilla Oberbarnscheidt, University of Pittsburgh Medical Center, Western Psychiatric Hospital

W105. Machine Learning Detection of Arousals From At-Home Sleep EEG Device Demonstrates Comparable Performance to Expert Raters in Sleep Disorders With and Without Antidepressant Use

Sarah Stankowicz*, Franz Furbass, Jack Sampiere, Antoine Guillot, Alexander M. Chan

Sarah Stankowicz, Beacon Biosignals

W106. Higher Polygenic Risk for Mitochondrial Dysfunction is Associated With Lower Cerebral Blood Flow in Youth With Bipolar Disorder

Nidhi Kulkarni*, Clement Zai, Kody Kennedy, Megan Mio, Ana Andreazza, Vanessa Goncalves, L. Trevor Young, Bradley MacIntosh, Benjamin Goldstein

Nidhi Kulkarni, Centre for Youth Bipolar Disorder, CAMH

W107. Choroid Plexus Volume as a Biomarker of Ketamine-Related Improvement in Irritability in Adults With Major Depressive Disorder

Megan Lean*, Amrita Ghose, Abu Minhajuddin, Manish Jha

Megan Lean, The University of Texas Southwestern Medical Center

**W108. Challenges and Strategies for Training and Retaining the Next Generation of Physician Scientists in Psychiatry During Residency and Fellowship**

Brian M Sweis, Simone Tomasi, Rene S Kahn, Antonia S New, Asher Simon, M. Mercedes Perez-Rodriguez*

M. Mercedes Perez-Rodriguez, Icahn School of Medicine at Mount Sinai

W109. Applying Scientific and Operational Insights From Prior Clinical Trials to Optimize Efficacy Signal Detection in a Proof of Concept Trial With KYN-5356 in Cognitive Impairment Associated With Schizophrenia

Nicholas DeMartinis, Elisa Yoritomi*, Jens Wendland, Heramb Chadchankar

Elisa Yoritomi, Kynexis Therapeutics, Inc.

W110. Initial Psychometric Properties of the Anhedonia Interview Rating Scale Clinician (AIRS) and Self-Report (AIRS-SR) Among Potential Psychiatry Study Participants

Jenicka Engler, Bryan Karazsia*, Sean Madden, Chris Kelly, Miriam Evans, Dyanna

Domilici, Marian Aquino, Cynthia McNamara, James Murrough

Bryan Karazsia, Cronos

W111. A First-In-Human Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of KYN-5356, a First-In-Class Inhibitor of Kynurenine Aminotransferase II (KAT-II)

Jens Wendland, Nicholas DeMartinis*, Heramb Chadchankar

Nicholas DeMartinis, Kynexis Therapeutics, Inc.

W112. Demographic and Clinical Characteristics of Participants Receiving COMP360 Psilocybin Treatment for Treatment-Resistant Depression Across Two Pivotal Phase 3 Trials

Nilay Hewitt, Rachael W. Taylor, Lindsey Marwood, Matthew Young, Guy Goodwin, Matt Young*

Matt Young, Compass Pathways, PLC

W113. Closing the Care Gap: Embedding PTSD Screening in Primary Care Workflows

Allison Mandell*, Kristen N. Benson, Morgan Smith, Jack Meullenet, Bradley Goodnight, Bharath Ravichandran, Jonathan Xue, Soma S. Nag, Ahmad Abdrabboh, Ferhat Ardic,

Brandon M. Kitay

Allison Mandell, Emory University School of Medicine

W114. Durability of Efficacy and Safety of COMP360 Psilocybin for Treatment-Resistant Depression (TRD) Across 26 Weeks in a Double-Blind, Randomized, Controlled Phase 3 Study

Guy M. Goodwin, Lindsay Marwood, Nilay Hewitt, Rachael Taylor, Jamie Chai-Rees,

Emma Teoh, Amanda Harring-Abbott, Sam Williams, Matthew B. Young, Michael Gold*

Michael Gold, Compass Pathways

W115. Elunetirom, a First-In-Class, Brain-Targeting, Antidepressant Candidate in Ph2 Development, Triggers Robust Bioenergetic and Neuroplastic Improvements in Preclinical Studies

Jason Harris*, Jill Baccei, Will Stratton, Thomas S. Scanlan, Gudarz Davar

Jason Harris, Autobahn Therapeutics, Inc.



W116. Lysergide Tartrate (LSD; DT120) Safety Profile From Phase 1 and Phase 2 Clinical Studies

Jessica Malberg*, Paula L. Jacobsen, PhD, Sarah M. Karas, PsyD, Jamileh Jemison, MD, MA, Nithya Srinivas, PhD, Daniel Karlin, MD, MA
Jessica Malberg, Definium Therapeutics

W117. Rational Deprescribing: ASCP Expert Consensus for Mood Disorders

Mauricio Tohen*, Joseph Goldberg, Anita Clayton
Mauricio Tohen, University of New Mexico

W118. The Association Between Ketamine and Esketamine and Urological Symptoms: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Gia Han Le*, Sabrina Wong, Joshua Rosenblat
Gia Han Le, Institute of Medical Science, University of Toronto

W119. Efficacy and Safety of Xanomeline/Trospium Chloride During Transition From Atypical Antipsychotics in Participants With Stable Schizophrenia Symptoms in EMERGENT-5

Craig Chepke, Brooke Kempf, James Appio, Andrew Thorpe, Gerard Zitnik*, Pierre Nicolas, Rajiv Radhakrishnan, Andrew J. Cutler
Gerard Zitnik, Bristol Myers Squibb

W120. Silence is Golden: Speech Production During Psilocybin Administration Sessions for the Treatment of Post-Traumatic Stress Disorder

Namik Kirlic*, Nadav Modlin, Niall McGowan, Patrick Staples, Ella Williams, Patrick Clarke, Mario Shafiei, Carly Leininger, Merve Atli, Megan Croal, Lindsey Marwood, Gregory Ryslik, Guy Goodwin
Namik Kirlic, Compass Pathways

W121. A Novel Interactive Digital Learning Tool (Discover TD®) for Psychiatry Resident Training on Diagnosis and Treatment of Drug-Induced Movement Disorders

Jasmine Modasi*, Bijal Sheth, M. Mercedes Rodriguez-Perez
Jasmine Modasi, Icahn School of Medicine at Mount Sinai

W122. Impact of a Three-Part Online Educational Webinar Series on Psychiatrists' Knowledge, Competence, and Confidence in Diagnosing and Managing Tardive Dyskinesia

Soumya Staton*, Leslie Citrome, Christoph U. Correll, Denise Vanacore Chase, Jovana Lubarda, Kathy Merlo, Austin Baiardi
Soumya Staton, Medscape Education

W123. Identifying and Predicting Symptom Trajectories in a Blended Hybrid Digital Mental Health Clinic

Elombe Calvert*, Tianyue Cong, Jin Soo Byun, John Torous
Elombe Calvert, Beth Israel Deaconess Medical Center

W124. Cognitive Impairment in Major Depressive Disorder: A Patient-Prioritized Target for Functional Recovery



Manish K. Jha, Philip D. Harvey, Dana DiBenedetti, Katherine Kosa, Leah Aluisio, Steven T. Szabo, Cecilia Brain, Jaskaran B. Singh, Neel Shah, Chris Wallick*
Chris Wallick, Neurocrine Biosciences, Inc.

W125. Evaluation of VedAI Across Clinical Psychiatry: A Blinded Psychiatrist-Rated Study

Anant Akash Sakthivel*, Vishnu Preye Sakthivel, Yasir Haji, Ritvij Satodiya
Anant Akash Sakthivel, Carolinas Psychiatric Institute

W126. Pharmacological Validation of Neurokit as a Portable, Sensitive and Reproducible Test Battery in Early Clinical Central Nervous System (CNS) Drug Development

Laura Borghans*, Olivier Ducazu, Vasileios Exadaktylos, Geert Jan Groeneveld, Gabriel Jacobs
Laura Borghans, Centre for Human Drug research

W127. Modeling Continuous-Time Network Dynamics of Passive Sensing and Ecological Momentary Assessment Data to Characterize Treatment Response in Digital Mental Health Care

Sam Cong*, Elombe Calvert, John Torous
Sam Cong, Beth Israel Deaconess Medical Center

Thursday, May 28, 2026 11:30 a.m. - 1:15 p.m.	Poster Session II with Lunch <i>Americana Ballroom</i>
---	--

YT1. Ketamine Treatment for Non-Motor Symptoms of Parkinson's Disease

Gerard Sanacora*, Mina Ansari, Lauren Astorino, Katherine Cioe, Marcus Hughes,, Sarah Jefferson, Sina Nikayin, Brian Pittman, Veronica Santini, Sherab Tsheringla, Sule Tinaz, Sophie Holmes
Gerard Sanacora, Yale University

T2. Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Remlifanserlin (ACP-204) in Healthy Adults

Mona Darwish*, Bryan Dirks, Amy Yamamoto, Brian Raether, Sanjeev Pathak
Mona Darwish, Acadia Pharmaceuticals Inc.

T3. Correlation of Plasma p-Tau217 and Csf p-Tau181 With Clinical Diagnosis of Alzheimer's Disease: A Cross-Sectional Study of 1,766 Participants in the Alzheimer's Disease Neuroimaging Initiative

Aishwarya Prasad*, Anshu Arora, Arun Arora, Mahima Patil, Arifulla Khan
Aishwarya Prasad, Northwest Clinical Research Center

T4. Assessing Community Pharmacist Preparedness to Implement Methadone Dispensing and Observation

Grace Marley*, Caroline Shubel, Delesha Carpenter, Bayla Ostrach
Grace Marley, University of North Carolina Eshelman School of Pharmacy

**T5. Understanding Kratom's Effects and Abuse Potential: Design of the First FDA-Funded Human Study**

James Thomas*, Frank Vocci, Ynhi Thomas, Adetola Vaughan, Thomas Kosten, Christopher Verrico

James Thomas, Baylor College of Medicine and Michael E. DeBakey VA Medical Center

**🏆 T6. Menstrual Phase-Driven Frontal White Matter Microstructural Dynamics Track
Progesterone and Craving Variability in Women With Substance Use Disorders**

Sarah King*, Yuefeng Huang, Nelly Alia-Klein, Rita Goldstein

Sarah King, Icahn School of Medicine at Mount Sinai

T7. Semaglutide for the Treatment of Opioid Use Disorder: Interim Analysis of a Pilot Randomized Controlled Trial

Kwadwo Owusu-Boaitey*, Alexander Wu, Dylan Campbell, Sarah Brassard, Anika Kopczynski, Naomi Rosenblum, Aishwarya Mahajan, Mary Shen, Jeong Hoo Lee, Zachary Sager, Samata Sharma, Olga Terechin, Vanita Aroda, Laura Holsen, Joji Suzuki
Kwadwo Owusu-Boaitey, Brigham and Women's Hospital

T8. Office-Based Treatment Retention Among Patients With Opioid Use Disorder and Recent Fentanyl Use: Extended-Release Injectable Buprenorphine vs Sublingual Buprenorphine

Brian J. Dawson, Dan Goulette, Eric Fox, Colin Cunningham, Adam Friedman, Carrie Kaempfer, Natalie R. Budilovsky-Kelley*, Joshua M. Cohen
Natalie R. Budilovsky-Kelley, Braeburn Inc.

T9. Real-World Utilization Trends of Weekly and Monthly Injectable Buprenorphine (CAM2038) in the United States During the Era of High Potency Synthetic Opioids

Michelle R. Lofwall, Michael P. Frost, Natalie R. Budilovsky-Kelley*, Adam Friedman, Carrie Kaempfer, Joshua M. Cohen
Natalie R. Budilovsky-Kelley, Braeburn Inc, Plymouth Meeting, PA

T10. The Pharmacokinetic Properties and Target Engagement Effects of the Novel Serotonin Transporter Modulator, SNTX-2643, in Healthy Adults

Andrew J. Cutler, Colville Brown*, Jacob Hooker, Jerry Rosenbaum
Colville Brown, Sensorium Therapeutics

T11. Efficacy and Safety of Ulotaront in Adults With Generalized Anxiety Disorder: Results From a Phase 2/3 Randomized Placebo-Controlled Trial

Brian Rothman*, Shivani Kapadia, Dalei Chen, Nicholas DeMartinis, Branislav Mancevski, Robert Hayes
Brian Rothman, Otsuka Pharmaceutical Development and Commercialization, Inc.

T12. Mazindol IR/SR: A 50-Year Legacy Repositioned as a First-In-Class Orexin-Monoamine Modulator for ADHD and Arousal-Related Disorders

Eric Konofal*, Jean-Charles Bizot, Bruce Corser, Michael J. Thorpy, Christelle Peyron, Jeffrey H. Newcorn, Michel Lecendreux, Sharon Wigal, Tim Wigal, Clete A. Kushida, Bruno Figadere, Isabelle Arnulf
Eric Konofal, University of Paris, Robert-Debré Hospital, France



T13. Comprehensive Multitarget Strategy for Type 1 Diabetes and Associated Neurological/Sleep Disorders (DANS): Integrating Stem-Cell-Derived Islet Replacement, Immune Modulation, and Neuro-Circadian Therapeutics

Eric Konofal*, Michel Revel, Anh-Tuan Lormier, Maxime Robin, Kfir Molakandov
Eric Konofal, University of Paris, Robert-Debré Hospital, France

T14. Investigating the Safety, Efficacy, and Tolerability of Adjunctive Cariprazine Treatment to Psychostimulants in Adults With ADHD: A Preliminary Study

Alexandria Greifenberger*, Elssa Toumeh, Kathryn Fotinos, Tia Sternat, Irvin Epstein, Martin Katzman
Alexandria Greifenberger, START Clinic for Mood and Anxiety Disorders

T15. ASRS Outcomes Across Core and Expanded Symptom Domains After 6 Weeks of Centanafadine Treatment in Adults With ADHD: A Pooled Post hoc Analysis of Two Phase 3 Trials

Jeffrey Newcorn, Joel Young, Caroline L. Ward, Dorothee Oberdhan, Zhen Zhang, Paul Geiger, Lenard A. Adler*
Lenard A. Adler, NYU School of Medicine

T16. Executive Function Symptom Outcomes in Adults With ADHD Treated With Centanafadine: A Pooled Post hoc Analysis of Two Phase 3 Trials

Jeffrey H. Newcorn, Joel Young, Caroline L. Ward, Dorothee Oberdhan, Zhen Zhang, Paul Geiger, Lenard A. Adler*
Lenard A. Adler, NYU School of Medicine

T17. Pathophysiological Analysis of Autism Spectrum Disorder Focusing on Peripheral Blood Macrophages

Yuki Nishi*, Ryouhei Takada, Michihiro Toritsuka, Hiroaki Fukui, Yuya Honda, Masato Honda, Mitsuru Ishikawa, Hideyuki Okano, Manabu Makinodan
Yuki Nishi, Nara Medical University School of Medicine

T18. Psychotropic Prescribing Trends Within the Texas Juvenile Justice Department From 2016 to 2024

Navin Oorjitham*, Denise Baughn, Noah Wright, Evan Norton, Scott LePor, Jordan Westra, Joseph Penn, Jacques Baillargeon, Rocksheng Zhong
Navin Oorjitham, University of Texas Medical Branch

T19. Sleep Architecture in Participants With Insomnia Disorder Characterized by Phenotype: Objective Short Sleep or Objective Normal Sleep

Andrew Krystal, Dinesh Kumar, Jocelyn Y. Cheng, Margaret Moline*
Margaret Moline, Eisai Inc.

T20. Psilocybin-Assisted Psychotherapy for Cluster B Personality Disorders and Comorbid Treatment-Resistant Depression

Orly Lipsitz*, Ryan Brudner, Zoe Doyle, Erica Kaczmarek, Shakila Meshkat, Roger McIntyre, Joshua Rosenblat
Orly Lipsitz, University of Toronto

T21. Pharmacotherapies for Co-Occurring Stimulant Use Disorder and ADHD: A Network Meta-Analysis



Henrique Oliva*, Alejandra Pulido-Saavedra, Alisson Paredes-Naveda, Emerson Forselius, Marc Potenza, Oluwole Jegede, Gustavo Angarita
Henrique Oliva, Yale University School of Medicine

T22. Effects of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs/GLP-1s) Integration in Patients Utilizing Antipsychotics

Plaiphon Vaidyanuvatti, Golden Reeves, Jasmyn Brown*, Mujeeb Shad
Jasmyn Brown, Touro University Nevada

T23. Prevalence of Psychotropic Medication Use Among Patients With Chronic and Immune-Mediated Diseases: A Real-World Analysis Using Epic Cosmos

Natasha Mazinani*, Lynette Martinez, Sui-Ling Perez, Christopher Chang, MD PhD

FAAAAI

Natasha Mazinani, Florida International University Herbert Wertheim College of Medicine

YT24. Prospective Replication of an Eeg Biomarker for Predicting Changes in Attention in ALTO-203, an H3 Inverse Agonist

Joshua Jordan, Li Shen, Guhan Sundar, Chao Wang, Amit Etkin, Adam Savitz*

Adam Savitz, Alto Neuroscience

YT25. BH-200 (nelivaptan), a Vasopressin V1b Receptor Antagonist, in Genetically Defined Subgroups of MDD: Precision Targeting of Hpa-Axis Dysregulation in the Olive Phase 2 Program

Daniel Gehrlach, Christine zu Eulenburg, Bertram Müller-Myhsok, Evangelos Papanastasiou, Ani Damyanova, Hans Eriksson*

Hans Eriksson, HMNC Brain Health

T26. A Phase 2 Clinical Trial Exploring Efficacy and Safety of the Vasopressin V1b Antagonist BH-200, a Treatment for MDD, Evaluating the Performance of a Genetic Classification Tool to Identify a Subset of Patients With Larger Improvement

Christine zu Eulenburg, Daniel Gehrlach, Evangelos Papanastasiou, Ani Damyanova, Caren Strote, Lars Arvastson, Bertram Müller-Myhsok, Hans Eriksson*

Hans Eriksson, HMNC Brain Health

YT27. Forvisirvat (SP-624), a First-In-Human SIRT6 Activator with an Epigenetic Mechanism of Action, Currently in a Phase 2b-3 Study for the Treatment of Major Depressive Disorder

Joel Raskin*, Greg Rigdon

Joel Raskin, Sirtsei Pharmaceuticals

🏆 T28. Effect of Ketamine on Individual Symptoms of Depression in a Randomized Controlled Trial of Ketamine for Treatment-Resistant Depression

Shabnam Hossein*, Manivel Rengasamy, Rebecca Price

Shabnam Hossein, University of Pittsburgh

T29. Effects of Solriamfetol on Neuropsychological Outcomes in Patients With Obstructive Sleep Apnea in the Real-World Survey Study

Yaroslav Winter, Graham M.L. Eglit, Samantha Floam*, Ulf Kallweit

Samantha Floam, Axxome Therapeutics

**T30. Metabolic Profiles of Participants With Major Depressive Disorder With Insomnia Symptoms in a Phase 3 Trial of Seltorexant Versus Quetiapine Extended Release as Adjunctive Therapy**

Tam Nguyen-Cao, Gahan Pandina, Sofie Mesens, Lu Xia, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, Yanina Flossbach, Wayne C. Drevets, Gahan Pandina*
Gahan Pandina, Johnson and Johnson

T31. Decrease in Negative Mood and Increase in Positive Mood During 12 Months of Vagal Nerve Stimulation

Koen Demyttenaere, Bernhard T. Baune, James Blackwell, Maxine Dibué, Christoph Kraus, Fritz-Georg Lehnhardt, Shannon Majewski, Christine Reif-Leonhard, Norbert Scherbaum, Maria Strauß, Allan Young, R. Hamish McAllister-Williams, Koen Demyttenaere*
Koen Demyttenaere, University Psychiatric Center KU Leuven

T32. Use of a Prospective Lead-In Study to Enhance Eligibility and Reduce Screen Failure in Major Depressive Disorder Trials

Harrison Gillman*, Hadley Nolan, Zach Cole, Colin Sauder
Harrison Gillman, Adams Clinical

T33. Metabolic Burden, Inflammation, and Esketamine Efficacy in Treatment-Resistant Major Depressive Episodes

Favour Olaoluwa*, Suzannah Wojcik, Edward Horn, Stefan Trivunovic, Jessica Clausen, Kelly Mascioli, Richard Kohl, Areebah Ahmed, Glenda O'Hara, Jess G. Fiedorowicz, Pierre Blier, Jeanne Talbot, Jennifer L. Phillips
Favour Olaoluwa, University of Toronto Scarborough

T34. Real-World Clinical Outcomes of Patients Switching to Treatment With Dextromethorphan-Bupropion (45 mg/105 mg)

Joel Young, Courtney Zeni*, Shawn Alter, Zhishui Zheng, Qi Qin, Yang Zhao
Courtney Zeni, Axsome Therapeutics

T35. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: Findings From Two Early-Terminated Phase 3 Trials

Clotilde Guidetti*, Anna Chiara Frigo, George I. Papakostas, Sara De Martin, Andrea Mattarei, Stefano Comai, Luca Pani, Charles Gorodetzky, Frank Vocci, Thomas Kosten, Franco Folli, Marco Pappagallo, Paolo L. Manfredi, Stephen M. Stahl, Maurizio Fava
Clotilde Guidetti, Massachusetts General Hospital, and Harvard Medical School

T36. Lumateperone Versus Other Adjunctive Atypical Antipsychotics for Major Depressive Disorder: A Network Meta-Analysis of Comparative Efficacy and Safety

Andrew Cutler, Anaïs Lemye, Qiaoyi Zhang, Carol Mao, Todor I Totev, Marjolaine Gauthier-Loiselle, Yujie Wu, Jingyi Liu, Mahmoud Hashim, Madhav Namjoshi, John J Sheehan, Dominic Pilon, Patrick Lefebvre, Antoine El Khoury, Leslie Citrome, Andrew J. Cutler, MD*

Andrew J. Cutler, MD, SUNY Upstate Medical University; Neuroscience Education Institute

T37. A Phase Ib Study Evaluating Safety, Preliminary Efficacy, and Putative Biomarkers of Neuroplasticity for the Novel Neuroplastogen Zalsupindole (DLX-001) in Major Depressive Disorder

Retsina Meyer*, Dan Gillie, David Olson, Eliseo Salinas, Hugh Nolan, Florentine Barbey



Retsina Meyer, Delix

T38. Real-World Effectiveness of Intravenous Ketamine on Depressive Symptoms, Suicidal Ideation and Functional Impairment in Adults With Mood Disorders

Sara Di Luch*, Nelson Rodrigues, Danica Johnson, Diana Orsini, Gabrielle Lovell, Shreya Vasudeva, Orly Lipsitz, Zoe Doyle, Rodrigo Mansur, Roger McIntyre, Joshua Rosenblat
Sara Di Luch, University of Toronto

T39. Evaluating the Association Between Antidepressant Efficacy and Dissociation With Ketamine in Treatment-Resistant Bipolar Depression (TRBD)

Sara Di Luch*, Nelson Rodrigues, Diana Orsini, Gabrielle Lovell, Shreya Vasudeva, Roger McIntyre, Rodrigo Mansur, Joshua Rosenblat
Sara Di Luch, University of Toronto

T40. Adjunctive Lumateperone 42 Mg Treatment in Major Depressive Disorder: Efficacy Across Patient-Reported Depression Symptoms

Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Alvin Oung*, Rakesh Jain
Alvin Oung, Intra-Cellular Therapies

T41. First Onset and Duration of Treatment-Emergent Adverse Events in Patients With Major Depressive Disorder Treated With Adjunctive Lumateperone 42 mg: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials

Willie Earley, Suresh Durgam, Susan G. Kozauer, Changzheng Chen, Margaret Martin*, Andrew J. Cutler, Stephen M. Stahl
Margaret Martin, Intra-Cellular Therapies

T42. Remission With Lumateperone 42 Mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials

Raffaele Migliore, Suresh Durgam, Willie R. Earley, Changzheng Chen, Eleni Mastromihalis*, Michael E. Thase
Eleni Mastromihalis, Intra-Cellular Therapies

T43. Peripheral Biomarker Reliability in Major Depressive Disorder: A Meta-Analysis of S100B

Sara Rose Shannon*, Umit Tural, Michael Kuhl, Dan Iosifescu
Sara Rose Shannon, Nathan S. Kline Institute for Psychiatric Research

T44. Evaluating the Abuse Liability of Ketamine in the Treatment of Mood Disorders: A Systematic Review

Shreya Vasudeva*, Gabrielle Lovell, Sabrina Wong, Gia Han Le, Diana Orsini, Sara Di Luch, Roger S. McIntyre, Joshua D. Rosenblat
Shreya Vasudeva, University of Toronto

T45. Patterns of Real-World Antipsychotic Switching After Initiating Adjunctive Cariprazine or Lumateperone in Adults With Major Depressive Disorder

Jeffrey R. Strawn, Rahul Khairnar*, Enrico Zanardo, Kaixin Zhang, Susannah Ripley, François Laliberté, Nadia Nabulsi
Rahul Khairnar, AbbVie



T46. Costs Associated With Adjunctive Atypical Antipsychotic–Related Weight Gain Among Patients With Major Depressive Disorder: An Economic Model Using Numbers Needed to Harm

Leslie Citrome, Rahul Khairnar*, Nadia Nabulsi, Huiying Guo, Simranpreet Waraich, Enrico Zanardo, Susannah Ripley, François Laliberté, Mousam Parikh
Rahul Khairnar, AbbVie

T47. Preclinical Evaluation of Ropanicant, a Nicotinic Acetylcholine $\alpha 4\beta 2$ Receptor Antagonist in Animal Models of Depression

Renny Abraham, Rajesh Babu Medapati, Narender Ganuga, Shankar Reddy Gagginapally, Srinivasa Rao Ravella, Narsimha Bogaraju, Vinod Kumar Goyal, Santosh Kumar Pandey, Surendra Petlu, Ramkumar Subramanian, Keerthi Sai Bitra, Vijay Benade, Ramakrishna Nirogi*
Ramakrishna Nirogi, Suven Life Sciences

T48. Ropanicant (SUVN-911), an $\alpha 4\beta 2$ Nicotinic Antagonist: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Evaluating the Efficacy and Safety of Ropanicant in Patients With Major Depressive Disorder (MDD)

Ramakrishna Nirogi*, Abdul Rasheed Mohammed, Veera Raghava Chowdary Palacharla, Vijay Benade, Satish Jetta, Vinod Kumar Goyal, Ramkumar Subramanian, Santosh Kumar Pandey, Ilayaraja Kalaikadhiban, Dhanunjaya Dogiparti, Pradeep Jayarajan, Anil Shinde, Venkat Jasti
Ramakrishna Nirogi, Suven Life Sciences

T49. Concurrent Oral Antidepressant Use and Clinical Outcomes From Intravenous Ketamine or Intranasal Esketamine in a Real-World Sample

Morgan Hardy*, Erin Curran, Greg Rhee, Rachel Katz, Samuel Wilkinson
Morgan Hardy, Yale University School of Medicine

T50. Psilocybin Treatment for Chronic Neuropathic Pain and Depression

Jordana Kazdan*, Karim Ladha, Venkat Bhat, Daniel Blumberger, Hance Clarke, Akash Goel, Brett Jones, Tyler Kaster, Joel Katz, Paul Ritvo, Daphne Voineskos, Wei Wang, Duminda Wijeyesundera, Ishrat Husain
Jordana Kazdan, Centre for Addiction and Mental Health, University of Toronto

T51. Convergent Validity and Treatment Responsiveness of the Patient-Rated Depression Checklist (PRDC)

Moses Njuguna*, Larry Alphs
Moses Njuguna, Princeton University

T52. An Investigation of the Putative Antidepressant Mechanisms of Ketamine, Reelin, and Mu Opioid Receptor Agonists in Rats and iPSC-Derived Cerebral Organoids Exposed to Chronic Stress

Ciara Halvorson*, Jenessa Johnston, Hector Caruncho, Carlos Zarate
Ciara Halvorson, other

T53. A Language-Derived Affective Sentiment Dimension of Ketamine Response in Depression

Ted Obi*, Vincent Holstein, Nicolas Grundman, Joan Camprodon, Michael Kritzer, Benjamin Wade
Ted Obi, Massachusetts General Hospital



T54. Interpreting Psychiatric Digital Phenotyping Data With Large Language Models: A Preliminary Analysis

Matthew Flathers*, Winna Xia, Christine Hau, Benjamin Nelson, Jiaee Cheong, James Burns, John Torous

Matthew Flathers, Beth Israel Deaconess Medical Center and Harvard Medical School

T55. A Simulation-Based Framework for Characterizing Risk in Clinically-Deployed Large Language Models

Mark Kalinich*, James Luccarelli, Frank Moss, John Torous

Mark Kalinich, Beth Israel Deaconess Medical Center

T56. AI-Enabled Patient-Derived Neuronal Models for Mechanism-Guided Antidepressant Selection in Major Depressive Disorder

David Pattison*, Talia Cohen Solal, Daphna Laifenfeld, Orit Goldman, Etay Aloni

David Pattison, NeuroKaire

T57. Sustained Pharmacodynamic Effects of Esketamine on Cortical Excitability and Resting-State Brain Activity: A Randomized, Placebo-Controlled Trial

Catherine de Cuba*, Annika de Goede, Joost van Mechelen, Laura Borghans, Maria Juachon, Robert Jan Doll, Amy Gillespie, Catherine Harmer, Gabriel Jacobs, Jules Heuberger

Catherine de Cuba, Centre for Human Drug Research

T58. ALTO-207, a Fixed-Dose Combination of Pramipexole and Ondansetron, Suggests Efficacy in Treating Major Depression: Findings From a Randomized, Double-Blind Phase 2a Trial

Joshua Jordan, Patricio O'Donnell, Timothy Peters-Strickland, Kathleen Clarence-Smith, Thomas Chase, Michael Browning, Amit Etkin, Adam Savitz*

Adam Savitz, Alto Neuroscience

T59. Effects of Alixorexton on Patient-Reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type 1: Results From the Phase 2 Vibrance-1 Study

Yves Dauvilliers, Ronald Grunstein, Emmanuel Mignot*, Gert Lammers, David Plante, Erik Buntinx, Rafael del Río Villegas, Hailu Chen, Craig Hopkinson, Bhaskar Rege, Julie Himes, Michael Doane, Giuseppe Plazzi

Emmanuel Mignot, Stanford University School of Medicine

T60. Safety and Efficacy Results From the Phase 2 Vibrance-1 Study of the Orexin 2 Receptor Agonist Alixorexton in Patients With Narcolepsy Type 1

Giuseppe Plazzi, Ronald Grunstein, Emmanuel Mignot, Gert Lammers, David Plante*, Erik Buntinx, Rafael del Río Villegas, Hailu Chen, Alexandra Lovett, Craig Hopkinson, Bhaskar Rege, Julie Himes, Yves Dauvilliers

David Plante, University of Wisconsin School of Medicine and Public Health

T61. The Use of Magnetoencephalography (MEG) in a First-In-Human Trial to Demonstrate the Functional Consequences of Target Engagement by DT-101, a Novel Ampa Receptor Positive Allosteric Modulator

Jennifer Swettenham*, Rasha Hyder, Natalie Jones, Neil Harrison, Krish Singh, Simon Ward, John Attack

Jennifer Swettenham, Draig Therapeutics



T62. Cross Trial Identification of a Predictive Enrichment Subgroup for Esmethadone (REL 1017) in Major Depressive Disorder Using Explainable Machine Learning

Joseph Geraci, Jan Sedway*, Christian Cumbaa, Bessi Qorri, Mike Tsay, Paul Leonchyk, Larry Alphas, Luca Pani
Jan Sedway, NetraMark

T63. Prediction of Human Pharmacokinetic Profiles of Glyph Platform Prodrugs Using Animal and Human Data via a Semi-Mechanistic Pharmacokinetic Model

Kosalaram Goteti*, Daniel K. Bonner, Michael C. Chen
Kosalaram Goteti, Seaport Therapeutics

T64. Evaluating Potential Abuse-Related Adverse Events in Clinical Studies of Psychedelics and Novel Central Nervous System Active Drugs to Inform Labeling and Scheduling Recommendations: Issues, Methods, and Recommendations

Ryan Lanier*, Marion Coe, Caitlyn Durgin, Judy Ashworth, Jack Henningfield
Ryan Lanier, Pinney Associates

YT65. DT-101 – a Novel alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Receptor (AMPA) Positive Allosteric Modulator Demonstrates Favorable Tolerability and Functional Biomarkers in Phase 1 Healthy Volunteer Trial

Simon Ward*, Jennifer Swettenham, Rasha Hyder, Ruth Lock, Krish Singh, John Attack
Simon Ward, Draig Therapeutics

T66. Using Artificial Intelligence/Machine Learning and Real-World Data to Identify Patients With Early Stage Bipolar-I Disorder for Whom an Aripiprazole Monohydrate LAI is Likely to Be a Favorable Treatment Option

Mauricio Tohen, Jason Jones, Bharath Ravichandran*, Karimah S. Bell Lynum, Norman Atkins, Jr., Soma Nag, Kristine Harrsen, Anne M. Hutson Walker, Tiffany Yu, Bartek Augustyniak, Isaac Kirk-Koffi, Jr., Vincent Marino, Rachel Linker, Christoph U Correll
Bharath Ravichandran, Guidehouse Consulting

T67. Do Nondsm Criteria Enhance the Validity of the DSM-5 Mixed Features Specifier in Depressed Patients?

Mark Zimmerman*, Madison Arnold, Julianna Schweitzer
Mark Zimmerman, Brown University

T68. Multifocal Negative Affect: The Prevalence and Clinical Profile of Psychiatric Outpatients who Are Depressed, Anxious and Irritable

Mark Zimmerman*, Matthew Snyder
Mark Zimmerman, Brown University

T69. The McIntyre and Rosenblat Rapid Response Scale (MARRRS): A Psychometric Evaluation of Patients With Treatment-Resistant Bipolar Depression

Nelson Rodrigues*, Roger S. McIntyre, Diana Orsini, Sara Di Luch, Gabrielle Lovell, Shreya Vasudeva, Rodrigo Mansur, Joshua D Rosenblat
Nelson Rodrigues, University of Windsor

T70. Changes in Sleep Patterns With Psilocybin-Assisted Psychotherapy: An Exploratory Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression



Erica Kaczmarek*, Zoe Doyle, Ryan Brudner, Shakila Meshkat, Roger S. McIntyre, Joshua D. Rosenblat

Erica Kaczmarek, University of Toronto

T71. Psilocybin for Anhedonia: A Systematic Review of Clinical and Preclinical Evidence

Erica Kaczmarek*, Sabrina Wong, Noah Chisamore, Danica Johnson, Zoe Doyle, Maya Stern, Anavi Parekh, Roger S. McIntyre, Rodrigo Mansur, Joshua D Rosenblat

Erica Kaczmarek, University of Toronto

T72. Don't Let AI Make You Moody: Assessing Racial Bias in Large Language Models' Clinical Decision-Making in Mood Disorders

Tracy Van*, Melanie Rovel, Huy Pham, Katelyn Grillo, Christian Grillo, Jose Rey
Tracy Van, Barry and Judy Silverman College of Pharmacy Nova Southeastern University

T73. Evaluating the Potential Risk of Ketamine-Induced Hepatotoxicity in the Treatment of Mood and Anxiety Disorders: A Systematic Review

Gabrielle Lovell*, Shreya Vasudeva, Diana Orsini, Sara Di Luch, Sabrina Wong, Gia Han Le, Roger S. McIntyre, Eddie Y. Liu, Joshua D Rosenblat

Gabrielle Lovell, University of Toronto

T74. Cognitive Outcomes Following Serial Ketamine Infusions in Treatment-Resistant Bipolar I/II Depression: Results From a Randomized, Midazolam-Controlled Trial

Danica Johnson*, Diana Orsini, Nelson Rodrigues, Sara Di Luch, Gabrielle Lovell, Shreya Vasudeva, Rodrigo Mansur, Roger McIntyre, Joshua Rosenblat

Danica Johnson, University of Toronto

T75. A Pilot Study of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Empagliflozin in Major Depressive Disorder

David Liebers*, Naomi Gaggi, Marcus Goncalves, Umit Tural, Dan Iosifescu

David Liebers, New York University School of Medicine

T76. Efficacy of Cariprazine for Anhedonia Symptoms: A Pooled Analysis of Patients With Major Depressive Disorder and Bipolar I Depression

Roger S. McIntyre, Jeffery R. Strawn, Zsófia Borbála Dombi, James Fratanterio, Maija Krumins, Simranpreet Waraich*

Simranpreet Waraich, AbbVie

🏆 T77. Differential Effects of Transcranial Photobiomodulation on Functional Network Reorganization Across Clinical Populations

Naomi Gaggi*, Karl-Heinz Nanning, Andres Rivera, Katherine Collins, Ricardo Osorio, Paolo Cassano, Dan Iosifescu

Naomi Gaggi, New York University Grossman School of Medicine

T78. Comparison of the Efficacy of Neuromodulation Therapies in Schizophrenia: A Systematic Review and Network Meta-Analysis

Rajasumi Rajalingam*, Samantha Dorrance, Marissa Khury, Daryna Hodgson, Vinay Patel, Aaryan Kapoor, Christine Sun, Aiswarya Lakshmi Nandakumar, Eric Achtyes

Rajasumi Rajalingam, Western Michigan University Homer Stryker M.D. School of Medicine

**T79. Harmonizing Adverse Event Criteria to Improve CNS-Related Safety and Abuse Signal Detection in Clinical Trials**

Denise Milovan*, Cynthia Arons, Thomas Hudzik, Beatrice Setnik, Berra Yazar-Klosinski
Denise Milovan, Altasciences Inc

T80. Real-World Experience and Impact of Cognitive Impairment in Narcolepsy and Idiopathic Hypersomnia From the ASPIRE Survey Study

Michael Doane*, Gretchen Murphy, Jane Lazar Tucker, Kristen McCausland, Lindsay Jesteadt, Claire Wylds-Wright
Michael Doane, Alkermes, Inc.

T81. A Head-To-Head Assessment of VMAT2 Target Occupancy of Once-Daily Valbenazine Compared to Deutetrabenazine Extended Release

Daniel Albrecht*, Satjit Brar, Wei Hou, Hui Zhang, Gena Riggs, Shannon Ingersoll, Jessica Maynard-Scott, Ryan Terry-Lorenzo, Ava Nguyen, Zeynep Demir, Christine Sandiego, Cristian Constantinescu, Eugenii A. Rabiner, David S. Russell, Dietrich Haubenberger
Daniel Albrecht, Neurocrine Biosciences, Inc.

T82. Opioid Use in Patients With Fibromyalgia: A Retrospective Claims Analysis

Errol Gould, Alonzo Whyte*
Alonzo Whyte, Tonix

T83. Complications of an Abrupt Switch From a Full Antagonist to a Partial D2 Agonist

Marian Banh*, Mujeeb Shad
Marian Banh, Western University of Health Sciences

T84. IMPACT-2: A Phase 2 Randomized, Dose-Response Trial of TSND-201 (Methylone) for the Treatment of PTSD

Amanda Jones*, Ashley Lauritsch, Stephanie Galinos, Jennifer Warner-Schmidt, Martin Stogniew, Blake Mandell, Benjamin Kelmendi
Amanda Jones, Transcend Therapeutics

T85. Symptoms of Post-Traumatic Stress Disorder in Individuals With Moderate-To-Severe Methamphetamine Use Disorder and Changes With Tirzepatide Treatment

Annsley Martin*, Virgilio Garza, Amrita Ghose, Teresa Slettebo, Nandini Jha, Elizabeth Dedrick, Snoben Kuruvila, Manish Jha
Annsley Martin, The University of Texas Southwestern Medical Center

T86. A Systematic Literature Review on Anti-Psychotic Utilization in Minority Populations and Key Clinical Considerations

Jasmyn Brown, Misbah Alam*, Momilani Tupu, Emily Tran, Jessica Nguyen, Jameson Chua, Mustafa Alam, Zain Hazari, Abdul Khan, Saba Saleem, Mujeeb Shad, Faisal Suba
Misbah Alam, The Valley Health System

T87. DT120 (Lysergide, LSD): Assessing the Potential Risk of Cardiac Valvulopathy After Chronic Dosing in Rats

Julie Tripp*, Jonathan Carter, Francesca Chianini, Gennady Smagin
Julie Tripp, Definium Therapeutics

T88. Real-World Treatment Patterns in Manic/Mixed Bipolar I Disorder: A Us Retrospective Cohort Study



Julia Forman*, Flavia Ejzykowicz, Vishnu Laxman, Weihua Gao, Lauren Moran
Julia Forman, Bristol Myers Squibb

T89. ML-007C-MA, a Novel Investigational M1/M4 Muscarinic Agonist in Phase 2 Development for the Treatment of Schizophrenia and Alzheimer's Disease Psychosis

Andrew Czysz, Heather Dworak, Emily Johnson, Kelly Amaguin, Randall Owen, Rosalin Arends, Michael W. Wood, Susmita Chatterjee, Maritza Soria, Abraham Vazquez, Natalie Navarro, Kimberly R Thompson*, Anatol C. Kreitzer, James Lillie, Erin Foff
Kimberly R Thompson, MapLight Therapeutics

T90. Efficacy of Xanomeline and Trospium Chloride Across Symptom Domains in Adults With Schizophrenia: Results From the 52-Week, Open-Label EMERGENT-5 Clinical Trial

Tracy Hicks*, John Kane, James Appio, Monica Elias, Pierre Nicolas, Amy Claxton, Lara Shirikjian
Tracy Hicks, C-Trilogy Outreach/BMS

T91. The Metabolic-Cognitive Pathway in Schizophrenia: Examining Fasting Glucose, Lipids, and Blood Pressure as Predictors of Cognitive Impairment and Dementia Risk

Bahareh Jabbari*, Jill Lally, Christopher Marano
Bahareh Jabbari, Bahareh Jabbari

T92. Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia

Peter J. Weiden, MD*, Jelena Kunovac, MD, MS, Shifang Liu, PhD, Daniel J. Kim, PhD, James A. McGrory, PhD
Peter J. Weiden, MD, Renaissance School of Medicine at Stony Brook University

T93. Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia

Peter J. Weiden, MD, Jelena Kunovac, MD, MS, Shifang Liu, PhD, Daniel J. Kim, PhD*, James A. McGrory, PhD
Daniel J. Kim, PhD, Alkermes, Inc.

T94. LB-102 for Acute Schizophrenia in Adults: Results From the Phase 2 NOVA1 Clinical Trial, Focused on PANSS Total Score Responder and CGI-S Remitter Rates

Christoph U Correll, Anna Eramo, Rezi Zawadzki, George Nomikos*, Leslie Callahan, Niccolo Bassani, John Kane
George Nomikos, LB Pharmaceuticals Inc

T95. Role of GLP-1 Receptor Agonists in Managing Antipsychotic-Related Metabolic Dysfunction and Weight Gain

Abdul Khan*, Areeba Nisar, Mustafa Alam, Saba Saleem, Muhammad B. Memon, David Abram, Misbah Alam, Faisal Suba
Abdul Khan, Valley Health System

T96. Real-World Use of Xanomeline and Trospium Chloride in Schizophrenia: Patient Characteristics, Treatment Patterns, and Outcomes

Jose Rubio, Yichen Zhong, Kristin Gillard*, Chi Gao, François Laliberté
Kristin Gillard, Bristol Myers Squibb



T97. Real-World Comparison of Olanzapine/Samidorphan Vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder

Hemangi R. Panchmatia, MSc*, Rakesh Jain, MD, Alejandro G. Hughes, MPH, Michael J. Doane, PhD, Craig Chepke, MD, Andrew J. Cutler, MD
Hemangi R. Panchmatia, MSc, Alkermes, Inc.

T98. Real-World Outcomes and Psychological Predictors in an 8-Week Hybrid Digital Clinic for Depression and Anxiety

Katherine Lim*, Rebekah Bodner, John Torous
Katherine Lim, Beth Israel Deaconess Medical Center

🏆 T99. Resting-State EEG Signatures of Suicidal Ideation Severity and Intensity in Treatment-Resistant Depression: Preliminary Baseline Data From Two Ongoing Clinical Trials

Gia Han Le*, Sabrina Wong, Orly Lipsitz, Danica Johnson, Noah Chisamore, Erica Kaczmarek, Lee Phan, Simryn Selby, Zoe Doyle, Benjamin Schwartzmann, Faranak Farzan, Rodrigo Mansur, Joshua Rosenblat, Roger McIntyre
Gia Han Le, Institute of Medical Science, University of Toronto

T100. Attitudes Toward Artificial Intelligence Clinical Decision Support in Psychiatry Training: Current Evidence and Future Directions

Andy Ngo*, Misbah Alam, Daniel Aynlender, Alex Makebah, Adrian Tran, Mujeeb Shad
Andy Ngo, Valley Health System

T101. The National Pregnancy Registry for Psychiatric Medications: Risk of Major Malformations Following Fetal Exposure to Second Generation Antipsychotics

Lee Cohen*, Marlene Freeman, Ana Manuelian, Bridget Murphy, Emma Grassi, Peri Barest, Skye Scoggins, Ella Slaby, Lily Cork, Hannah Dineen, David Chitayat, Sonia Hernandez-Diaz, Adele Viguera
Lee Cohen, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

T102. Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the Mgh National Pregnancy Registry for Psychiatric Medications

Marlene Freeman*, Adele Viguera, Ana Manuelian, Emma Grassi, Bridget Murphy, Lee Cohen
Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

T103. Risk of Major Malformations Following First Trimester Exposure to Cariprazine: Preliminary Data From the Mgh National Pregnancy Registry for Psychiatric Medications

Adele Viguera*, Marlene Freeman, Ella Slaby, Ana Manuelian, Peter Gaccione, David Chitayat, Sonia Hernandez-Diaz, Lee Cohen
Adele Viguera, Cleveland Clinic

T104. Artificial Intelligence–Assisted Participant Recruitment for Psychiatric Clinical Trials: A Comparative Evaluation of Lead Quality and Engagement



Alexander Bystritsky*, Kate Seletckaia, David Bozin, Alexis Poche, Michelle Piesman, Alejandra Cortez, Alexis Rosas, Mayra Acevedo
Alexander Bystritsky, UCLA/Brainsonix/CalNeuroResearch/ABCanxiety/WNT/IACS

T105. Active and Passive Digital Phenotyping to Measure Outcomes in a 12-Month Study of Xanomeline/ Trospium Chloride in Schizophrenia: Longitudinal Prediction of Total Changes With Early Levels of Physical Activity

Philip Harvey*, William Horan, Andrew Cutler, Daniel DeBonis, Patrick Harrington, Steve Brannan
Philip Harvey, University of Miami Miller School of Medicine

T106. Exosomes and a Novel Mitochondrial Mechanism of Epigenetic Regulation of Brain Plasticity in Treatment Resistant Depression

Benedetta Bigio*, Amarjyot Singh, Josh Dobbin, Olivia Barnhill, Yotam Sagi, Sean O'Sullivan, Igor D. Bandeira, Nick Bassano, Marin Kautz, Ashly Cochran, James Kocsis, Francis Lee, James Murrough, Alan F. Schatzberg, Carla Nasca
Benedetta Bigio, New York University School of Medicine

T107. Perspectives of Nurse Practitioners and Physician Associates on Presenting Long-Acting Injectables to Adults With Schizophrenia: A Delphi Panel Study

Daphne Weeks, Sonny Cline, Kody Green, Jason Gray*, Karen Johnston, Laura Morrison, Lilian Diaz, Neema Lema, Dominic Pilon, Leslie Citrome
Jason Gray, Johnson and Johnson

T108. A Novel, Brain Penetrant Kat-II Inhibitor, KYN-5356, Reduces Brain Kynurenic Acid Levels and Enhances Glutamatergic and Cholinergic Transmission

Heramb Chadchankar, Nicholas DeMartinis*, Robert Schwarcz, Carol Tamminga, Jens Wendland
Nicholas DeMartinis, Kynexis Therapeutics, Inc.

T109. Racial Differences in Antidepressant Initiation and Outcomes After a One-Time Psychiatric Consultation: A Mixed-Methods Study

Helena Kim*, Ishrat Husain, Stefan Kloiber, Benoit H. Mulsant
Helena Kim, Centre for Addiction and Mental Health, University of Toronto

T110. Efficacy and Safety of COMP360 Psilocybin for Treatment-Resistant Depression (TRD) in Two Phase 3 Double-Blind Randomized Controlled Studies

Guy Goodwin, Lindsay Marwood, Nilay Hewitt, Rachael Taylor, Jamie Chai-Rees, Emma Teoh, Hollie Simmons, Amanda Harring-Abbott, Sam Williams, Ryan Bastle*, Michael Gold
Ryan Bastle, Compass Pathways

T111. Esketamine Nasal Spray for Relapse Prevention in Patients With Treatment-Resistant Depression: A Post Hoc Analysis of Predictors of Relapse in Placebo-Treated Patients in SUSTAIN-1

Richard Shelton, Ibrahim Turkoz, Dong-Jing Fu, Mai Himedan, Lisa Lim, Oliver Lopena, Alexis Davis, Manish Patel, Toya Bowles*
Toya Bowles, Johnson and Johnson

T112. Validation of the Neurokit Platform for Central Nervous System Pharmacodynamic Assessment in Healthy Volunteers



Erin Tireman*, Clay Dehn, Vasileios Exadaktylos, Janeen Rosales, Lance Ballester, Bailey Cox, Alina Beaton, Gabriel Jacobs, William Martin
Erin Tireman, Lotus Clinical Research

T113. Connectedness as a Mechanism of Change in Psilocybin-Assisted Cognitive Behavioral Therapy

Lorenzo Miller*, Marc Weintraub, Cordelia Kuiper Rauch, David Miklowitz
Lorenzo Miller, David Geffen School of Medicine at UCLA

T114. Next-Generation Pharmacotherapies for Mood and Anxiety Disorders: A Comprehensive Review of Phase II/III Drug Development Across Diverse Mechanisms

Alana King*, Morgan Hardy, Greg Rhee, Samuel Wilkinson
Alana King, Yale University School of Medicine

T115. Open-Label, Randomized Study to Assess Safety and Efficacy of Slow and Accelerated Switching to Xanomeline/Trospium From Standard of Care Atypical Antipsychotics in Participants With Schizophrenia

David Walling*, Naomi Marbot, Lara Shirikjian, Edwin Gomez, Lauren White, Kimball Johnson, Pierre Nicolas, Andrew Thorpe, Gerard Zitnik, Scott Vuocolo, Ken Kramer
David Walling, CenExel - CNS

T116. From Nightmares to Depression: Age-Stratified Neuropsychiatric Effects of Montelukast

Saba Saleem*, Ali Abbas, Rabail Abbas, Mujeeb Shad, Faisal Suba
Saba Saleem, Valley Health System

T117. Improvement of Predominant Negative Symptoms in Patients With Schizophrenia on Paliperidone Palmitate 6-Month Long-Acting Injectable: Post-Hoc Analysis Over 3 Years

Jordy Mehawej*, José Antunes, Ibrahim Turkoz, Leslie Killion, R. Karl Knight, Christoph U. Correll
Jordy Mehawej, Johnson and Johnson

T118. Efficacy of Sublingual Dexmedetomidine in the Home Setting for Reduction in Agitation Across Baseline Severity of Symptoms in Patients With Schizophrenia or Bipolar Disorder

Michael De Vivo*, Lavanya Rajachandran, Heather Robison, Rashmi Deshpande, Dusan Kostic
Michael De Vivo, BioXcel Therapeutics

T119. Long-Term Metabolic and Cardiovascular Safety and Tolerability With Xanomeline and Trospium Chloride: Pooled Results From EMERGENT-4 and EMERGENT-5

James Appio, Rajiv Radhakrishnan, Pierre Nicolas, Scott Vuocolo*, Ken Kramer
Scott Vuocolo, Bristol Myers Squibb

T120. Randomized Study to Assess Safety and Efficacy of Slow and Accelerated Switching to Xanomeline/Trospium From Standard of Care Atypical Antipsychotics in Participants With Schizophrenia

David Walling, Naomi Marbot, Lara Shirikjian, Edwin Gomez, Lauren White, Kimball Johnson, Pierre Nicolas, Andrew Thorpe, Gerard Zitnik, Scott Vuocolo*, Ken Kramer



Scott Vuocolo, Bristol Myers Squibb

T121. Outcomes in Depression Symptomatology With High and Low Levels of Suicidal Ideation

Audrey Shoultz*, Brandon Knight, Andrew van der Vaart, Scott T. Aaronson
Audrey Shoultz, Sheppard Pratt

T122. Real-World Safety and Effectiveness of Lurasidone in Chinese Children and Adolescents With Schizophrenia: A Post-Hoc Analysis of a Post-Marketing Surveillance Study

Lei Zhang, Yumei Wei*, Yifeng Shen
Yumei Wei, Secretary of GCP Office

T123. Real-World Evidence of Clinical Treatment Response Following Intravenous Racemic Ketamine Versus Intranasal Esketamine in Adults With Major Depressive Disorder

Robert Dougherty*, Samuel Wilkinson, Emily Shih, Jamie Lo, Jimmie Qian
Robert Dougherty, Osmind

T124. Multiclass Environmental Toxicants Found in Cerebrospinal Fluid (CSF) and Plasma Samples From Pregnant Women: Potential Associations With Postpartum Depressive Symptoms

Bushra Amreen, Corina Lesseur, Ravikumar Jagani, Hiraj Patel, Daniel Katz, Joshua Hamburger, Noel Strong, Leah Habersham, Anna Rommel, Lotje De Witte, Chris Gennings, M. Mercedes Perez-Rodriguez*
M. Mercedes Perez-Rodriguez, Icahn School of Medicine at Mount Sinai

T125. Continuous Multimodal Passive Monitoring of Depressive Symptoms via Smartphone: Clinical Validation of a Novel Digital Health Technology

Antony Perzo*, Michael Todd Sapko, MD, PhD, Tanel Petelot, Renaud Séguier, Jonathan C Javitt, MD, MPH
Antony Perzo, EMOBOT

T126. Comparable Symptom Improvement With Electroconvulsive Therapy and Esketamine in Transgender and Gender Non-Conforming Adults With Treatment-Resistant Depression

Ariyaneh Nikbin*, Kapil Chauhan, Marcus Hughes
Ariyaneh Nikbin, Yale